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ABSTRACT  
For early breast cancer (EBC) patients, local relapse represents what mostly influences 
disease outcome. Surgery itself and the consequent process of wound healing have been 
proposed to stimulate local recurrences via pathway(s) still to be clarified. Notably, 90% of 
local recurrences occur at or close to the same quadrant of the primary cancer. p70S6K and 
STAT3 pathways have been implicated in breast cancer cell response to post-surgical 
inflammation, supporting the hypothesis that they may be crucial also for breast cancer 
recurrence. The results of this PhD thesis show that interfering with p70S6K activity strongly 
impaired breast cancer cell survival in vitro and local relapse in vivo. Peri-operative treatment 
using specific pharmacological inhibition of p70S6K1 was sufficient to reduce by 83% the 
rate of local recurrence. The significance of our results was confirmed in human EBC 
specimens, proving that p70S6K activity is consistently increased by surgery, also in human 
patients. Our study also highlighted that surgical fluids very efficiently activated STAT3 and 
that STAT3 activity was necessary for the survival and growth of tumor initiating cells. Taken 
together, our results show that p70S6K and STAT3 pathway are strongly involved in the 
promotion of the survival of residual tumor cells in the breast microenvironment.  
Moreover, we demonstrate that p70S6K is an important regulator of breast cancer progression 
and could be used as target to restrain recurrent disease and to improve clinical outcomes in 
EBC patients. Finally, we show that STAT3 impinges on breast cancer stem cell phenotype 
upon WF stimulation and its precise role in the insurgence of local recurrence is currently 
under investigation. 
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1.1 Breast Cancer 
 
Breast cancer is the most frequently diagnosed cancer in women worldwide and the second 
leading cause of cancer-related death. More than 1-2 million cases are diagnosed every year, 
affecting 10–12% of the female population and accounting for 500,000 deaths per year 
worldwide (1). In the last two decades, mortality rates have generally remained stable or 
decreased. Declines in breast cancer mortality have been attributed to both novel treatment 
strategies and early detection due to the implementation of screening/prevention programs (2). 
However, more than 120,000 estimated deaths due to breast cancer are expected annually in 
the US and Europe combined (3, 4). Breast cancer is not a single disease: it is instead a 
collection of breast diseases that are heterogeneous in terms of histology, genetic and genomic 
variations, therapeutic response and patient outcomes. From a clinical point of view, breast 
cancer can be subdivided into three major subtypes: tumors expressing estrogen receptors 
(ERs) and/or progesterone receptors (PRs), tumors expressing amplified form of human 
epidermal receptor 2 (HER2-amplified) and tumors commonly referred to as triple-negative 
breast cancer (TNBC), due to lack of or low positivity for ER, PR and HER2 (5). These 
markers together with other clinical parameters (age, node status, tumor size, histological 
grade) are routinely used in the clinic to stratify patients for prognostic predictions and 
treatment selection. However, the complexity of breast cancer diseases is not entirely 
reflected by the parameters described. Studies based on global gene expression analyses have 
provided important new classifications of cancer patients based on variations in their gene 
expression profiles that correlated with prognosis (6-9). The studies of gene expression 
profiling reported by Perou et al. have established five breast cancer intrinsic subtypes 
(Luminal A, Luminal B, HER2-enriched, Claudin-low, Basal-like) and a Normal Breast-like 
group. Importantly, the intrinsic subtypes segregated tumors by expression of hormone 
receptors (both ERs and PRs), supporting earlier epidemiologic and biomarker studies. 
Among the ER-positive tumors, two major subtypes, luminal A and luminal B, have been 
identified. These subtypes are biologically distinct in that luminal A tumors tend to have 
higher expression of ER related genes and lower expression of proliferative genes than 
luminal B (6-9). Among the ER-negative tumors, the major subtypes are the HER2-enriched 
subtype and the basal-like subtype. The first group shows elevated expression of HER2 and of 
many other genes residing near HER2 in the genome. The basal-like subtype includes the 
triple-negative breast cancer and display high proliferative rate compared with other subtypes 
(6-9). Importantly, these subtypes have been shown to be clinically meaningful, and can 
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divide patients into groups with distinct tumor histotypes and distinct outcomes. 
Comprehensive characterization of molecular subtypes requires whole genome profiling 
which is not routinely performed in the clinical setting. For this reason, as mentioned before, 
the different classes of tumors are distinguished more easily by expression of the ER, PR, and 
HER2 receptors that are routinely performed to guide therapy decisions.  For breast cancer 
patients, several treatment options are currently available in neoadjuvant or adjuvant settings. 
These include hormone therapies, targeted therapies, radiotherapy and various chemotherapy 
regimens. Breast cancer patients with positive ER, PR and HER2 status are responsive to 
targeted therapeutics given as monotherapy, or in combination with chemotherapy. A number 
of hormonal therapeutic agents have been approved for the treatment of ER positive disease, 
including tamoxifen, aromatase inhibitors and fulvestrant. For HER2 positive breast cancer, a 
growing number of HER2-targeted agents have become available, including trastuzumab, 
lapatinib and pertuzumab (5, 10).  
 
1.2 Local Recurrence in Early Breast Cancer 
 
The systemic use of widespread mammographic screening has contributed to a stage shift for 
newly diagnosed disease, increasing the percentage of early breast cancer (EBC) at diagnosis. 
In women with EBC all detectable cancer is restricted to the breast and, in women with node-
positive disease, to the local lymph nodes. Breast conserving therapy, including primary 
tumor excision, axillary node dissection (determined in advance or decided following sentinel 
node sampling) and external radiotherapy (RT), is considered standard of care for 
management of women with early-stage breast cancer (11). For EBC patients the appearance 
of local relapse (LR, defined as the reappearance of malignant disease in the ipsilateral breast) 
represents a common event that may influence the prognosis. Several studies have shown that 
the presence of local recurrence is the strongest independent predictor of distant relapse and 
confers an increased risk of up to three-fold to four-fold (11, 12). Importantly, it was 
demonstrated that local recurrence formation is not merely associated with distant relapse but 
is causally related, indicating that local relapse is a determinant and not simply an indicator of 
risk of distant metastasis (13). The relapse of the disease in breast cancer occurs in one in five 
patients and represents the principal cause of breast cancer-related deaths (14).  The relative 
risk of distant metastases for patients developing local relapse in comparison with patients 
without local relapse is considerable and, in fact, patients who develop LR present a 
substantially worse overall survival (15-17). The importance to restrain local recurrences in 
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breast patients was highlighted in a recent overview that conclusively showed that treatments 
substantially improving local control have definite effects on long-term survival, representing 
one life saved for every four loco-regional recurrences prevented (18).  
The effects of external radiotherapy on local recurrence as well as on distant recurrence and 
long-term overall survival were recently extensively analyzed. A recent meta-analysis by the 
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) has demonstrated that local 
radiation treatment to either the breast after breast-conservation surgery or the chest wall after 
mastectomy induced an overall survival benefit at 15 years (18). In particular, radiotherapy 
reduces the recurrence rate by half and the death rate by about a sixth in patients that have 
undergone breast conserving surgery. Results of the EBCTCG overview have reinforced the 
link between local control and mortality, emphasizing the importance of achieving the best 
loco-regional treatment for this kind of patients.  
Interestingly, it was observed that a differential pattern of recurrence between different breast 
cancer subtypes exists (19-21). In particular, patients with luminal A (ER-positive) tumors 
had the most favorable prognosis, with LR of 8% at 10 years; conversely, TNBC patients 
exhibited a rate of 14% (22). Also the mean time to local relapse was shorter in patients with 
TNBC tumors than other breast cancer subtypes (23).  
Clinical and experimental data suggest that the perturbation induced in the tumor 
microenvironment by surgery itself and the subsequent wound healing process may result in 
stimulation of postsurgical disease (24-26). From a clinical point of view, 90% of local 
recurrences occur at or close to the same quadrant of the primary cancer, despite multifocality 
is very common in breast cancer (27). Three-dimensional analysis of mastectomy specimens 
showed that 63% of breasts harbour occult cancer foci, with 80% of these situated remote 
from the index quadrant. However, the cancers in other quadrants of the breast appeared to 
remain dormant for many years and have a low risk of causing clinical tumors (27). 
Moreover, the results of a randomized clinical trial comparing mastectomy and 
quadrantectomy showed that early relapses were more frequent in the mastectomy than the 
quadrantectomy group. This difference, which disappeared later on during follow-up, is 
consistent with an acceleration of metastatic burden in the first years after invasive surgery 
(28). These clinical observations support the idea that local disease develops from re-growth 
of residual cancer cell in peritumoral tissue in response to surgical wounding. Experimental 
data in animal models, show that the surgical trauma enhances the proliferation of metastatic 
foci, supporting the hypothesis that, at least in mice, surgery should be considered as a major 
perturbing factor for metastasis (25). Some evidences highlighted that also in human breast 
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cancer, surgical removal of the primary tumor may induce changes in the growth kinetics of 
micro-metastasis, similarly to what observed in animal models (25). Indeed, many similarities 
between the stroma at sites of wound repair and reactive stroma in cancer can be observed, 
including inflammation, chemotaxis, angiogenesis and extracellular matrix production (29, 
30). Since tumor progression requires continuous interactions between neoplastic cells and the 
microenvironment, a favorable wound healing stroma might promote the growth of residual 
cells into a tumor. The correlation between wound response and cancer progression was also 
supported by the analysis of gene expression profile of normal tissue adjacent to cancer that 
evidences the activation of a “wound response signature” able to promote cancer progression 
(31). The in vivo wound response signature is highly prognostic of breast cancer survival and 
suggests the idea that microenvironment represents an important variable for breast cancer 
progression, especially when a wound response is activated by surgical excision (31). Other 
studies performed in mice have shown the presence of growth stimulating factors in mouse 
serum after removal of the primary tumor (32). Recently, our (33) and other (34) in vitro 
studies demonstrated the stimulatory effect of post-surgical drainage fluids (hereafter referred 
to as wound fluids, WF) on breast cancer cells proliferation and invasion. Work from other 
groups reported that WF, as well as postsurgical serum samples, induce proliferation of 
HER2-positive breast carcinomas, signifying that at the site of surgery growth factors able to 
induce cell proliferation are produced (34). In our work, we found that WF collected from 
early breast cancer patients undergone to breast surgery, stimulated cancer cells growth, 
migration and invasion (33), supporting the role of surgery as perturbing factor for recurrence 
formation, also in human patients. Moreover, we evaluated whether treatment with intra-
operative radiotherapy, such as TARGIT (Targeted Intraoperative RadioTherapy), may reduce 
local recurrence by killing residual tumor cells and also by affecting tumor microenvironment 
(33). TARGIT-A trial was launched on 2000 to test whether intraoperative radiotherapy might 
be considered an alternative to external radiotherapy (27, 35). Intraoperative radiotherapy 
delivers a high dose of radiation as one fraction at the time of surgery, allowing precise 
application of radiation dose to the target area around the surgical bed. The clinical relevance 
of one single application of TARGIT was recently reported, demonstrating that intraoperative 
treatments are much more effective than previously hypothesized (35). Our previous results 
(33) and clinical observations (35) suggest that this could be due, at least in part, to the 
alteration of the microenvironment and to the modulation of the wound healing response 
induced by intra-operative radiotherapy. In fact, our data clearly demonstrated that WF 
derived from TARGIT-treated patients were defective in stimulating breast cancer cell 
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proliferation and invasion, compared with WF from patients treated only with surgery (33). 
Moreover, we highlighted the importance of two pathways in this response, the p70S6K and 
the STAT3 pathway. The activation of these pathways is high when breast cancer cells are 
stimulated with surgical fluids but is impaired in the presence of WF derived from TARGIT-
treated patients (33). For this reason, and given the clinical benefit observed in TARGIT–
treated patients, we hypothesized that p70S6K and STAT3 could represent two key regulators 
in the mechanisms of local relapse in EBC patients. 
 
1.3 p70S6K signaling and breast cancer 
 
The PI3K/mTOR/p70S6K axis is known to regulate many processes that are critical for 
tumorigenesis such as cell growth, proliferation, survival and metabolism (36). Briefly, the 
activation of PI3K (phosphatidylinositol 3-kinase) and the production of the lipid second 
messenger PIP3 (phosphatidylinositol 3,4,5-trisphosphate) from PIP2 triggers the recruitment 
and activation of Akt (protein kinase B) by the phosphatidylinositol-dependent kinases, PDK1 
and PDK2 (37). One of the major effectors downstream of Akt is mTOR. Akt phosphorylates 
and inactivates the tuberous sclerosis complex (TSC) tumor suppressor, leading to the 
activation of the mammalian target of rapamycin complex 1 (mTORC1, hereafter mTOR) 
signaling pathway that results in the activation of p70S6K (38) (Figure 1). 
The described pathway is inappropriately activated in many cancers by receptor tyrosine 
kinases, as well as by the genetic mutation and amplification of other key pathway 
components. The aberrant activation of this pathway plays a major role in breast cancer and 
many evidences suggest that it is linked to promotion of breast cancer cell survival, resistance 
to chemotherapy, resistance to endocrine therapy, and it is associated with poor prognosis, 
advanced stage and histological grade (39-41). 
mTOR is a conserved central regulator of cell proliferation and growth and integrates signals 
from multiple inputs such as growth factors, stress, nutrients, and energy to regulate protein 
synthesis, cell cycle progression, actin organization, and autophagy (42, 43). Because of these 
essential roles, deregulation of mTOR is prominent in the development and progression of 
cancer and in metabolic diseases, such as diabetes and obesity. Two families of mTOR 
substrates have been characterized: the ribosomal protein S6 kinases (S6K1–2), and the 
eIF4E-binding proteins (4EBP1–3). 4E-BP1 is a repressor of the translation initiation factor 
eIF4E and thus an inhibitor or protein biosynthesis; the phosphorylation triggered by mTOR 
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disrupts its interaction with eIF4E allowing eIF4E to bind and form a functional initiation 
complex (Figure 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Schematic representation of PI3K/mTOR/p70S6K pathway. Mitogenic signals 
(growth factors, cytokines and hormones) act on receptor tyrosine kinases (RTKs), stimulating 
PI3K that in turn stimulates the Akt pathway. Akt activates mTORC1 which phosphorylates 
and activates ribosomal S6 kinases (S6Ks) (adapted from Silvera et al., 2010). 
 
 
Opposite to 4E-BP1, S6K phosphorylation results in its activation and in initiation of the 
translation machinery through activation of several regulators of protein synthesis (42-46). 
The ribosomal protein S6 kinase family comprises two homologous proteins, S6K1 and 
S6K2, each of which are found as two alternatively spliced isoforms (p70S6K and p85S6K). 
Both S6K1 and S6K2 are downstream of mTOR pathway and present same redundant 
functions. The p70 kDa isoform of S6K1 (p70S6K1) is the best-studied S6 kinase, it is 
ubiquitously expressed and localizes predominantly to the cytoplasm (47).  
S6K1 belongs to the AGC kinase family, a subgroup of serine/threonine protein kinases. AGC 
kinases activation is dependent on the phosphorylation of two regulatory motifs: an activation 
loop and a hydrophobic motif (37). For S6K1, the best characterized sites are Threonine 229 
(T229) in the activation loop and Threonine 389 (T389) in the hydrophobic motif. mTOR 
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phosphorylates T389, relaxing the conformation of the kinase and creating a docking site for 
PDK1, which is then able to phosphorylate T229 in the activation loop (48).  
S6K1 plays important roles in cell growth, proliferation, and cell differentiation by regulating 
protein synthesis, cell cycle progression, and metabolism (49-51). The principal substrate of 
the S6Ks is the ribosomal protein S6, one of 30 distinct ribosomal proteins, which together 
with 18S rRNA, constitutes the smaller 40S ribosomal subunit (52). The phosphorylation of 
S6 is a highly conserved event and occurs in five serine residues proceeding in a sequential 
fashion: S235-S236-S240-S244-S247. p70S6Ks are able to carry out the phosphorylation of 
all five sites (53, 54). 
The physiological role of S6K was studied through genetic studies in Drosophila and mice. 
S6K-/- flies and mice are much smaller than wild type and this reduction in body size is due 
to a reduction in individual cell size rather than cell number, suggesting that S6K mostly 
regulates cell growth rather than proliferation (51, 55, 56). However, in S6K1 knock-out mice 
S6K2 expression is upregulated and appears able to restore phosphorylation of S6 to levels 
close to those of wild type mice in all tissue examined, suggesting that S6K2 can cooperate 
and also substitute S6K1 in the phosphorylation of S6 (56, 57). Other targets of p70S6K have 
been reported, some of which include other regulators of protein synthesis such as the 
eukaryotic elongation factor 2 kinase (eEF2K), the eukaryotic translation initiation factor 4B 
(eIF4B), the translational inhibitor PDCD4 and the RNA-binding protein SKAR (58-61). 
S6K1 is able to phosphorylate also mTOR at Threonine 2446/Serine 2448, indicating that a 
potential feedback loop may exist (62) (Figure 2).  
 
 
 
 
 
 
 
 
 
 
Figure 2. Key downstream effectors of S6K signaling. The image show the S6K 
downstream substrates and the cellular function in which are implicated (adapted from Fenton 
and Gout, 2010). 
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The complexity is increased by the fact that, although mTOR is known to be the primary 
regulator of S6K, other upstream activators of p70S6K were identified. For example, it was 
recently demonstrated that GSK-3 positively regulates S6K1 activity and cell proliferation, 
suggesting also that the cooperation of other upstream molecules is important for full 
activation and functionality of S6K (50).  
In many cancers, the mTOR/S6K pathway is highly active because of mutations and/or 
overexpression of upstream positive regulators such as PI3K, Akt, and HER2, or loss of 
expression or function of negative regulators such as the tumor suppressors PTEN and 
TSC1/2. Recent studies have addressed the specific role of S6K1 in tumor proliferation, 
invasiveness, motility and angiogenesis (63, 64). In particular, many data suggest the 
involvement of p70S6K also in breast cancer onset and/or progression. p70S6K1 is encoded 
by the RPS6KB1 gene, localized to the chromosomal region 17q23. Comprehensive analysis 
of the 17q23 region revealed a limited number of highly expressed genes that may contribute 
to the more aggressive clinical course observed in breast cancer patients with 17q23-amplified 
tumors. It was observed that RPS6KB1 was amplified in 59 (8.8%) of 668 primary breast 
tumors and in several breast cancer cell lines, leading to the overexpression of the protein (65-
68). It is to note that, while amplification of this region has been observed in several tumor 
types, high copy number amplification occurs in breast cancer specifically (68). Further 
evidence in support of a role for p70S6K1 in tumor development and progression comes from 
the observation that RPS6KB1 amplification and overexpression are associated with poor 
prognosis in an unselected series of breast cancer patients (67). Interestingly, in a study 
exploring the phosphorylation and activation of different members of the PI3K/Akt/mTOR 
pathway, phosphorylation of p70S6K (in T389 residue) has been found elevated 10- to 35-
fold in breast cancer cells compared to normal primary mammary epithelial cells (69). 
Moreover, more than 70% of invasive breast carcinomas, have been demonstrated to possess 
high levels of phosphorylated p70S6K and, in sharp contrast, phosphorylation of the same 
protein was nearly undetectable or was at low levels in normal mammary tissues under the 
same assay (69). 
Interestingly, overexpression of p70S6K protein is linked to increased risk of locoregional 
recurrence in node-negative EBC patients, thus specifically suggesting a role for this kinase as 
prognostic marker (70). Since frequent deregulation in the PI3K/AKT/mTOR/p70S6K 
signaling pathway was observed in different type of tumors, many efforts have been 
employed to develop several inhibitors at different levels of this pathway (5, 36). Among 
others, mTOR inhibitors are the most highly developed of this pathway. The first mTOR 
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inhibitor discovered was rapamycin, which is a macrolide that was originally found as an 
antifungal agent and was later recognized as having immunosuppressive and anticancer 
properties (71, 72). The mechanism of action of rapamycin is not completely understood. The 
complex of rapamycin with its intracellular receptor FKBP12 binds directly to mTORC1 and 
suppresses mTORC1-mediated phosphorylation of the substrates. Many rapamycin derivates 
were developed explicitly designed for development as anti-cancer drug (71). Despite the 
substantial pre-clinical data indicating that rapamycin and its analogues have anti-tumor 
effects and that mTOR participates in many cancer-related pathways, these molecules have 
not shown universal anti-tumor activity in early clinical trials. There are many reports of 
rapamycin promoting pro-apoptotic stimuli (73, 74) but there are also reports of it promoting 
cell survival (75, 76). It has been shown in breast tumors and in many cancer cell lines that 
inhibition of mTOR with rapalogs releases a negative feedback loop, resulting in re-activation 
of AKT. Despite the many strong correlative clinical and experimental observations, the role 
of p70S6K in the process of breast cancer relapse has never been investigated nor p70S6K has 
been exploited as a therapeutic target. 
 
1.4 STAT3 signaling and breast cancer 
 
Inflammatory conditions can initiate or promote oncogenic transformation and cancer 
associated inflammation is marked by the presence of specific inflammatory cells and 
inflammatory mediators, including cytokines and chemokines (77). Recent evidences suggest 
a crucial role for Signal Transducer and Activator of Transcription (STAT) family proteins, 
especially STAT3, in selectively inducing and maintaining a pro-carcinogenic inflammatory 
microenvironment, both at the initiation of malignant transformation and during cancer 
progression (78, 79). STAT3 belongs to the STAT family of proteins, which are both signal 
transducers and transcription factors. At least seven members in this family have been 
identified, which are encoded by distinct genes. Structurally, STAT proteins have the 
following distinct domains: the N-terminal, coiled-coil, DNA binding, the Linker, Src 
homology 2 (SH2) and C-terminal transactivation domains. Each of these domains has a 
distinct function. For example, the N-terminal domain is important in STAT dimer-dimer 
interactions; the DNA binding domain forms complexes between STAT proteins and DNA; 
the SH2 domain engages in dimerization between two activated STAT monomers through 
reciprocal phospho-tyrosine (pTyr)-SH2 domain interactions, while the C-terminal portion of 
the protein functions as the transcriptional activation domain (79-81). STAT3 has important 
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roles in fundamental processes, including proliferation, development, differentiation, 
inflammation, and apoptosis (79-82). STAT3 is activated by non-receptor tyrosine kinases, 
such as JAK or Src and growth factor receptor, such as epidermal growth factor receptor 
(EGFR) and platelet-derived growth factor receptor (PDGFR) (83, 84). Upon the binding of 
growth factors or cytokines to their cognate receptors on the cell surface, STAT3 is recruited 
to the cytoplasmic portions of the receptors, where it becomes phosphorylated on Tyr 705 in 
the C-terminus. Cytokine receptors do not usually have intrinsic tyrosine kinase activity: 
instead, their engagement activates receptor-associated tyrosine kinases, most prominently the 
Janus kinase (JAK) family kinases that are able to phosphorylate STAT3. Tyrosine-
phosphorylated STAT3 then dimerizes through reciprocal pTyr-SH2 domain interactions, 
translocates into the nucleus and binds to specific STAT-response elements in the promoters 
of target genes, thereby inducing the transcription of those genes essential for its 
physiological functions (85-88) (Figure 3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Schematic representation of STAT3 pathway. Binding of growth factors or 
cytokines to their receptors results in the activation of intrinsic receptor-tyrosine-kinase 
activity or of receptor-associated kinases, such as the JAK or Src tyrosine kinases. These 
tyrosine kinases subsequently phosphorylate the cytoplasmic tails of the receptor to provide 
docking sites for the recruitment of monomeric STAT3. Once they have been recruited, 
STAT3 becomes substrates for tyrosine phosphorylation. Phosphorylated STAT3 dimerizes 
and translocates to the nucleus, where the dimers directly regulate gene expression (adapted 
from Yu and Jove, 2004). 
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STAT3 regulates the transcription of several genes, some involved in apoptosis, such as Bcl-
2, Bcl-xl, Mcl-1 and Survivin, others involved in cell cycle progression, such as Cyclin D1 
and others related to epithelial-mesenchimal transition, such as Twist1 and Vimentin (78-82) 
(Figure 4). It is to note that many of the downstream target genes of STAT3 encode cytokines 
and growth factors, the receptors of which signal through the same STAT3, thereby providing 
a mechanism for autocrine and paracrine STAT3 activation (85, 88-90). Under normal 
biological conditions, STAT3 activation is rapid and transient. However, STAT3 has been 
found to be hyper-phosphorylated and constitutively activated in a large number of solid 
tumors and in cell lines which often become addicted to its activity for continuous survival 
and growth (91, 92).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. STAT3 target genes. STAT3 upregulates the expression of genes that are required 
for proliferation and survival. These include the genes that encode c-MYC, cyclin D1 and 
cyclin D2, BCL-xl, MCL1 and Survivin. In addition, STAT3 negatively regulates the 
expression of p53. STAT3 signaling also stimulates tumor angiogenesis (adapted from Yu and 
Jove, 2004). 
 
The role of STAT3 in promoting transformation is well documented. Conditional knockout of 
the STAT3 gene or inhibition of STAT3 function blocked v-Src induced transformation in 
cancer model systems (93-95), indicating a pivotal role for STAT3 in malignant 
transformation. As an important proof for the oncogenic potential of STAT3, an artificially 
engineered, constitutively dimerized STAT3C alone is sufficient to induce malignant 
transformation of immortalized fibroblasts and tumor formation in mice (96). Gene 
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expression changes induced by constitutively active STAT3 represent critical molecular 
events that lead to the dysregulation of cell cycle control and apoptosis, thereby promoting 
cell growth and survival and contributing to malignant transformation and tumorigenesis. 
Despite many known pro-proliferative or anti-apoptotic target genes have been identified 
upon acute stimulation, they are not always consistently induced in tumors displaying lower 
but continuous STAT3 phosphorylation. The exact mechanisms by which constitutively 
active STAT3 mediates malignant transformation and human tumor formation are still 
incompletely understood and continue to be investigated. 
Constitutive activity of STAT3 was observed in 35% to 60% of human breast tumors and in 
many breast cancer cell lines in which is required for continuous proliferation and resistance 
to apoptosis. Since no STAT3 mutation was identified, constitutive activation of STAT3 in 
breast tumors is associated with the induction of the expression and/or the activity of the EGF 
receptor family kinases and of Src or also with aberrant JAK activity (97-101). Several studies 
have used different approaches to assess the expression, localization, phosphorylation, and 
DNA binding ability of STAT3 in breast cancer. One of these studies has found increased 
levels of nuclear localized STAT3 in comparison to normal surrounding tissues but no 
association with clinico-pathological or outcomes data were provided (102). Another study 
assessed the level of STAT3 and phospho-STAT3 in several samples of node-negative breast 
cancer patients and correlated these results with clinico-pathological and survival data (103). 
This study found that nuclear phospho-STAT3 expression was correlated with a modest, but 
statistically significant, improvement in patient survival both at 5 and 20 years. Data from in 
vitro studies have evidenced that pharmacological or dominant-negative inhibition of STAT3 
activity has been found to block the proliferation and survival of breast cancer cells in part by 
down-regulation of Bcl-xL, Bcl-2, Survivin and Mcl-1, and correlated well with the inhibition 
of human breast tumor growth in xenograft models (98, 100, 104, 105). However, little data 
exists regarding STAT3 -mediated gene up-regulation in malignant breast tissues and the 
specific contributions of the genes regulated by STAT3 during the pathogenesis of human 
breast cancer remain to be completely elucidated.  
Recently, some authors have reported the involvement of cytokine signaling via IL6 
receptor/STAT3 in the regulation of breast cancer stem cells (CSCs) self renewal and 
differentiation (106, 107, 110-113). Cancer stem cells or tumor initiating cells (TICs) are rare 
cells that are suspected to be responsible for tumor recurrence, formation of metastases, as 
well as chemoresistance (108, 109). It was demonstrated that activated JAK2/STAT3 
signaling is essential for the survival of CD44+/CD24-/low stem-like breast cancer cells (110) 
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and was shown to play an important role during mammosphere formation (111). STAT3 was 
also identified by a RNAi screen to be a critical player in mammosphere formation and self 
renewal of breast CSCs (112, 113). Despite the fact that a sizable body of evidences highlight 
that STAT3 is inappropriately activated in a vast percentage of breast tumors, its biological 
significance is not fully established and its concrete role in breast cancer initiation and/or 
progression is still very controversial.  
Since the discovery of the association of constitutive STAT3 activation with malignant 
transformation, a large number of studies have been undertaken for the validation of STAT3 
as a cancer drug target (114-116), and substantial efforts were employed into the discovery of 
novel STAT3 inhibitors. There is a large number of STAT3 inhibitors reported, with many 
different mechanism of actions. Of these inhibitors, a few show good activity in terms of the 
inhibition of STAT3 biological functions and the associated antitumor cell effects, as well as 
the inhibition of tumor growth in the mouse models of human tumors (116). These inhibitors 
are mostly at the experimental stage and not in the form considered to be suitable for clinical 
utility; in fact, up to now, only two drugs are in the first phase of clinical trial. 
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Breast cancer represents the most common malignancy in women worldwide. Local relapse 
represents what mostly influences the outcome in early breast cancer patients (EBC). Thus, 
the understanding of the mechanisms underlying this unfavorable clinical event represents a 
compelling objective in breast cancer research. Despite the fact that multifocality is a 
hallmark of most breast cancer, 90% of local recurrences occur at the same quadrant of the 
primary cancer, supporting the hypothesis that surgery itself and the consequent process of 
wound healing may represent a perturbing factor in the mechanism that lead to local re-
growth. Our previous work evidenced p70S6K and STAT3 signaling pathway as possible 
molecular mediators of breast cancer recurrence. In this PhD project, we aimed to dissect the 
role of p70S6K and STAT3 signaling pathways in the response of breast cancer cells to 
wound fluids and to understand their possible contribution in regulating the processes that 
provokes the insurgence of local recurrences. 
To this aim, we characterized the behavior of breast cancer cell lines with impaired p70S6K 
or STAT3 activity with particular interest to WF response. As additional approach, we used a 
novel specific pharmacological inhibitor of p70S6K1 and different compounds targeting 
STAT3. 
We designed an in vivo experimental model resembling the course of human breast cancer, in 
which breast cancer cells were injected in nude mice mammary fat pads and, when primary 
tumors were grown, masses were surgically removed under anesthesia. After recovering, mice 
were followed up to detect appearance of local relapse. 
Using this model, we dissected the role of p70S6K and STAT3 during breast cancer growth 
and recurrence by modulating their activity using both genetic and pharmacologic approaches. 
Our results show that p70S6K and STAT3 pathways positively affect the survival of residual 
breast cancer cells. We demonstrated that p70S6K is an important regulator during the 
process of breast cancer recurrence and could be used as target to restrain recurrent disease 
and to improve clinical outcomes in EBC patients. Moreover, we show that STAT3 impinges 
on breast cancer stem cell phenotype upon WF stimulation and its precise role in the 
insurgence of local recurrences is under evaluation. 
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3.1. Role of p70S6K signaling pathway in breast cancer recurrence 
 
3.1.1. Generation of breast cancer cell lines with altered p70S6K activity. 
Our previous studies demonstrated that wound fluids (WF) collected from the breast wound 
after surgery of EBC patients are very rich in cytokines and growth factors, stimulated breast 
cancer cell proliferation, motility and invasion, and induced a marked activation of the 
p70S6K pathway (33). Using a larger panel of breast cancer cell lines, we confirmed that 
activation of p70S6K signaling is a common event after exposure to WF (Figure 1A-B). The 
analysis of the p70S6K target phospho-S6 showed that, with few exceptions, 5% WF 
stimulated p70S6K signaling at even higher extent than 10% serum. 
To investigate whether activation of p70S6K was functionally involved in the response of 
breast cancer cells to WF, we generated breast cancer cell lines with altered p70S6K activity 
(Figure 2A-B and data not shown). We chose to use two triple negative carcinoma cell lines 
with highly aggressive phenotype, MDA-MB-231 and MDA-MB-453. To this aim, cells were 
transfected with a kinase inactive form of p70S6K (HA-p70KR, carrying the substitution 
K100R) (117) (Figure 2A) or transduced with lentiviral particles encoding for specific anti 
human p70S6K sh-RNA (Figure 2B). As additional approach, we also used a novel specific 
p70S6K1 inhibitor, PF-4708671 (hereafter PF) (118), as well as the clinically approved 
mTOR inhibitor, rapamycin analogue Temsirolimus (hereafter Tems). Cells were then 
stimulated with FBS or WF and activation of p70S6K evaluated (Figure 2A-C and data not 
shown). 
Our experiments clearly indicated that breast cancer cells responded to WF stimulation hyper-
activating p70S6K pathway and this activation was efficiently impaired when p70S6K 
pathway was blocked by different approaches. 
 
3.1.2. Characterization of proliferative and migratory behavior of breast cancer cell 
lines with altered p70S6K activity. 
We then analyzed the effects of alteration of p70S6K activity in proliferative and migratory 
behavior of cells. Since WF are rich in cytokines and growth factor, we used either WF or 
FBS as source of growth stimuli. In line with the well established role of p70S6K in cell 
proliferation, growth curve assay revealed that, when p70S6K activity was impaired, 
moderate but consistent decrease of cell proliferation was always observed (Figure 3A-B and 
data not shown). Consistently, growth of the parental cells in the continuous presence of PF or 
Tem led to a similar reduction of proliferation rate (Figure 3B). More importantly, using  
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Figure 1. In breast cancer cell lines, p70S6K is efficiently activated following stimulation 
with wound fluids.  
A. Western blot analysis of MDA-MB-231, MDA-MB-453 and MCF-7 cell lines serum 
starved and then stimulated for the indicated times with 10% serum (FBS) or 5% wound 
fluids (WF). B. Same as in (A), but using BT-474, BT-549, HBL-100 and SK-BR-3 cell lines, 
as indicated. Vinculin expression was used as loading control. 
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Figure 2. Activation of p70S6K following wound fluid (WF) stimulation is efficiently 
impaired in breast cancer cell lines modified for p70S6K expression or inhibited for its 
activity. A. Western blot analysis of MDA-MB-231 cell line stably transduced with a 
retroviral empty vector (CTR) or with a retroviral vector encoding for a kinase inactive 
mutant of p70S6K (KR), serum starved and then stimulated for the indicated times with 
wound fluids (WF).B. Western blot analysis of MDA-MB-231 cell line stably transduced with 
a lentiviral vector encoding for control sh-RNA (CTR) or for sh-RNAs directed against 
human p70S6K (sh), serum starved and then stimulated for the indicated times with wound 
fluids (WF).C. Western blot analysis of MDA-MB-231 cell line serum starved and then 
stimulated for the indicated times with wound fluids (WF) or serum starved, pre-treated 30 
minutes with the indicated inhibitor (PF-4708671 10 µM or Temsirolimus 100 nM) and then 
stimulated for the indicated times with WF, in the presence of the inhibitor. Vinculin 
expression was used as loading control. 
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Figure 3. Growth and motility of breast cancer cell lines is altered by impairing p70S6K 
activity. 
A. Growth curve analysis of MDA-MB-231 CTR or p70KR cells. Cells have been seeded on 
day 0, in complete medium (CM) or in the presence of 3% wound fluids (WF), as indicated, 
and then counted by Trypan Blue exclusion test, every day for 5 days. B. Growth curve 
analysis of MDA-MB-231 cell line in the presence of the indicated inhibitors. Cells have been 
seeded in medium containing 3% wound fluids (WF) on day 0, in the presence of PF-4708671 
(5 µM or 20 µM) or Temsirolimus (50 nM or 200 nM) or vehicle (untreated). C. Anchorage 
independent growth of MDA-MB-453 CTR or p70KR cells. Cells were included in soft agar 
in presence of complete medium (10% FBS) or 3% wound fluids (WF), for 3 weeks. Graph 
reports the count of colony number/field evaluated in each condition. D. Matrigel invasion 
assay of MDA-MB-231 CTR or p70KR cells or cells treated with the indicated inhibitor. 
Cells have been seeded on top of a transwell chamber, pre-coated with Matrigel, in the 
presence of 5% wound fluids (WF) plus PF-4708671 (10 µM) or Temsirolimus (100 nM), 
where indicated. The percent of invading cells after 12 hours is shown. E. Matrigel evasion 
assay of MDA-MB-231 CTR or p70KR cells. Cells were included in Matrigel in the presence 
of 5% wound fluids (WF) for 6 days, then fixed and analyzed for the distance covered from 
the edge of the drop.  
In all the experiments, data represents the mean (± S.D.) of two independent experiments 
performed in triplicate. In all panels, statistical significance was calculated using the Student’s 
t-test. A p value ≤ 0.05 was considered significant. 
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anchorage independent growth assays in soft agar, in the presence of either FBS or WF, we 
verified that impairment of p70S6K activity by expression of p70KR significantly decreased 
the cell ability to survive and grow (Figure 3C, CTR vs KR, in FBS p=0.002). In particular, 
when WF was used as source of survival and growth stimuli the difference was extremely 
significant (CTR vs KR, in WF p<0.0001). This suggested that, under this condition, the 
necessity for a robust p70S6K signaling was of particular relevance. 
Then, we looked at the possibility that alteration of p70S6K activity could affect the 
migratory and invasive behavior of breast cancer cells. We challenged cells in three-
dimensional (3D)-invasion or evasion assays, in order to more accurately mimic the in vivo 
microenvironment. Invasion of a 3D-matrix highlighted more significant differences between 
control cells and cells with impaired p70 signaling, particularly when p70S6K1, and not 
mTOR, was attacked (Figure 3D, CTR vs PF-treated p=0.003; Figure 3E, CTR vs KR 
p=0.015). Altogether, these results support the notion that p70S6K activity positively 
contributes to proliferation and invasion programs of breast cancer epithelial cells.  
 
3.1.3. Impact of p70S6K activity on primary tumor growth. 
To evaluate whether the impairment of p70S6K signaling would impact on breast 
tumorigenesis, we used an orthotopic xenograft model of breast cancer and injected MDA-
MB-231 control- or p70KR-cells in mouse mammary fat pads (MFP) using Matrigel to 
support their initial survival. As expected, results indicated that, under these conditions, 
impaired p70S6K activity strongly decreased primary breast tumor growth (Figure 4A and 
data not shown). Next, we injected decreasing numbers of MDA-MB-231 control- or p70KR-
cells and waited until tumors reached similar volumes before excising the masses. p70KR-
cells grew slower and reached the same tumor mass approximately one week later respect to 
controls (data not shown). Then, in order to challenge their ability to initiate tumor growth in 
more stringent conditions and possibly discern among the ability of p70S6K signaling to 
impact on proliferation or survival of breast cancer cells in vivo, we injected decreasing cells 
number in MFP without Matrigel. It is interesting to note how in this setting, an intact 
p70S6K signaling was extremely critical for tumor initiation (67% versus 0%, in control- and 
p70KR-cells, at low cell number, 1x105, n=12) (Figure 4B). More careful analysis of tumors 
arising from 2x105 and 4x105 injected cells suggested that impairment of p70S6K signaling 
significantly increased the tumor latency (9 versus 26 days, Figure 4C) but, once tumors 
appeared, their growth rate was very similar (Figure 4D). This observation pointed out that, in 
the process of tumor initiation, p70S6K signaling played a major role in survival rather than  
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Figure 4. Primary tumor growth is altered by impairing p70S6K activity. A. Growth 
curves, expressed as tumor volume (mm3), of primary tumors derived from injection of 
MDA-MB-231 cells (1x106) stably transduced with a retroviral empty vector (CTR) or with a 
retroviral vector encoding for a kinase inactive mutant of p70S6K (KR), in thoracic mammary 
fat pads of nude mice (2 MFP/mouse) in 50 µl Matrigel/PBS (1:1). Mice were sacrificed after 
3 weeks. Statistical significance was calculated using the Student’s t-test, pooling together 
values of the last measurement of controls vs p70KR. Three asterisks (***) indicate a p value 
≤ 0.005. B. Tumor take-rate assessed by injection of the indicated numbers of MDA-MB-231 
CTR or p70KR cells, in the presence or absence of Matrigel. C. Graph reports the time 
dependent appearance of primary tumors derived from injection of MDA-MB-231 CTR or 
p70KR cells (2x105and 4x105) in the nude mouse mammary fat pads (2 MFP/mouse) without 
Matrigel. Mice were sacrificed 7 weeks after injection. D. Graph reports the rate of tumor 
growth, independently from the time of appearance, in mice described in (C). Values are 
expressed as ratio of the tumor volume over the value of 20 mm3, considered as cut off. The 
red and the green lines represent the trend of growth of the MDA-MB-231 CTR and p70KR, 
respectively. E. Growth curves, expressed as tumor volume (mm3), of primary tumors derived 
from injection of MDA-MB-231 control cells (2x106), in the thoracic mammary fat pads of 
nude mice (2 MFP/mouse). Mice were intraperitoneally injected with PF-4708671 (25mg/kg, 
i.e. 600µg/mouse) or Temsirolimus (12.5mg/kg, i.e. 300µg/mouse) or vehicle (untreated), 
twice a week for three weeks. Data represent the mean (± S.D.) of 10 tumors/treatment. 
Statistical significance was calculated using the Student’s t-test, pooling together values of the 
last measurement. Three asterisks (***) indicate a p value ≤ 0.005. Difference in tumor 
volume between Untreated and PF-treated tumors was not significant (n.s.). 
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in proliferation of breast cancer cells. Next, to establish the role of p70S6K in a preclinical 
model, we used an alternative approach, mimicking a neo-adjuvant setting. We bilaterally 
injected MDA-MB-231 control cells in mouse MFP and, from appearance of a palpable mass, 
we treated mice with PF, Tems or vehicle twice a week, for three weeks. No particular 
sufferance or toxicity was observed during treatment, either with PF or Tems. In line with the 
established role of mTOR in cell growth, Tems treated mice displayed a considerable 
decrease in their tumor growth throughout the course of treatment (Figure 4E). Treatment 
with PF did not elicit a significant decrease in the growth of established primary tumors, 
indicating that specific p70S6K1 activity is not essential during this stage of tumorigenesis, in 
agreement with what observed using p70KR expressing cells (Figure 4C-D).  
 
3.1.4. Impact of p70S6K activity on breast cancer local relapse. 
The main goal of our study was to understand whether p70S6K played a role in the formation 
of breast cancer local recurrence. We designed an experimental model in vivo resembling the 
course of human breast cancer (Figure 5A). We bilaterally injected breast cancer cells in 
mouse MFP, waited for primary tumors to grow and surgically removed masses under 
anesthesia. After recovering, mice were followed up to detect manifestation of recurrence. 
After 8 weeks from surgery, mice were sacrificed and mammary glands, recurrences (if 
present) and lymphnodes were collected (Figure 5A). Since the impairment of p70S6K 
activity gave rise to smaller tumors (Figure 4A), we injected 1x106 control cells (left MFP) 
and 2x106 p70KR expressing cells (right MFP) in order to obtain, at surgery time, primary 
tumors of similar size and easily excisable (Figure 5B-C). Control mice showed a recurrence 
rate of 64% (Figure 5I). Strikingly, in p70KR-injected mice percentage of local relapse 
dramatically dropped to 18% (Figure 5I). Tumor spreading to loco-regional lymphnodes was 
detected only ipsilaterally to CTR cells-injected MFPs (Figure 5D). Similar results were 
obtained using MDA-MB-231 cells stably transduced with specific shRNA silencing p70 
(Figure 5I). Importantly, PCR analyses have excluded the possibility that recurrences 
observed in the left MFP (injected with control cells) could be caused by p70KR expressing 
cells incidentally attracted to the surgery site from circulation (Figure 5E). Detection of strong 
and consistent increase of S6 phosphorylation in all relapses respect to paired primary tumors 
(Figure 5F) further supported that p70S6K signaling was relevant during this process.  
 
 
RESULTS 
30 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
31 
 
Figure 5. Local recurrence of breast cancer is prevented by impairing p70S6K activity. 
A. Schematic representation of the experimental design, set up to evaluate the appearance of 
breast cancer recurrences. B. Growth curves, expressed as tumor volume (mm3), of primary 
tumors derived from injection of MDA-MB-231 CTR cells (1x106), in the left MFP or p70KR 
(2x106), in the right MFP of nude mice. Data represent the mean (± S.D.) of 5 tumors/cell 
type, measured during the time preceding surgery. C. Representative images of mice 
displaying similar size of primary tumors (upper panels) but resulting in the formation of local 
recurrence only in left MFP, injected with CTR cells (lower panels). D. Representative 
images of histo-pathological analysis of recurrences or residual mammary glands excised 
from mice described in (B), following haematoxylin and eosin staining. E. PCR on retro-
transcribed RNA extracted from primary tumors and/or recurrences, as indicated, using 
primers designed on the retroviral vector encoding for p70KR (1600 base pair, bp). F. 
Western blot analysis of primary tumor lysates and corresponding recurrent disease lysates 
(where present) from experiment described in (C). Pt: primary tumor, Rec: recurrence. 
Vinculin was used as loading control. G. Growth curves, expressed as tumor volume (mm3), 
of primary tumors derived from injection of MDA-MB-231 CTR cells (2x106), in nude mouse 
thoracic mammary fat pads. Mice were intraperitoneally injected with PF-4708671 (25mg/kg 
or 50mg/kg i.e. 600µg/mouse or 1200µg/mouse) or Temsirolimus (12.5mg/kg or 25mg/kg i.e. 
300µg/mouse or 600µg/mouse) or vehicle (untreated). Treatments were administered three 
times following a “peri-surgical schedule”. Data represent the mean (± S.D.) of 10 
tumors/treatment. H. The picture above shows the primary tumors, excised the day of surgery, 
from mice described in (G). The pictures below show representative images of an untreated 
mouse displaying recurrent disease and a PF-treated mouse with no recurrence, 8 weeks after 
surgery. I. Graph reports the disease free survival in the indicated cohorts of mice, after 
removal of the primary tumor. Data are reported as percentage of mice that developed 
recurrent disease during the 8 weeks of follow up.  
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3.1.5. Peri-operative treatment with specific p70S6K1 inhibitor, but not with mTOR 
inhibitor, is sufficient to restrain breast cancer local relapse. 
To exploit the possibility of therapeutically targeting p70S6K in breast cancer, we tested 
p70S6K1 specific inhibitor PF in vivo (119). In parallel, we also tested mTOR inhibitor Tems. 
We reasoned that restraining p70S6K activity during the surgery-induced inflammatory 
response would hamper residual cancer cells to locally survive and re-grow and, thus, we 
designed a three-days schedule of peri-operative treatment (day -1, day 0 and day +1, respect 
to surgery). We bilaterally injected MDA-MB-231 control cells in nude mice MFPs and, 
when primary tumors reached a volume of 200-300mm3, we treated mice with vehicle, PF or 
Tems (Figure 5G-H). Peri-operative treatment with PF was highly effective in blocking the 
formation of recurrences (Figure 5I; 64% in controls vs 23% in PF600µg and 11% in 
PF1200µg). Intriguingly, Tems was ineffective or even harmful to the mouse (Figure 5I, 64% 
in controls vs 67% of Tems 600µg). Statistical analysis demonstrated that treatment with high 
doses of PF was significantly more effective than treatment with high doses of Tems in 
reducing local relapse (p=0.03 in Logrank test; Hazard Ratio 6.7; 95% Confidence Interval 
1.1-56.1). Altogether, our in vivo experiments demonstrated that p70S6K signaling is 
involved in local relapse of breast cancer and its specific inhibition significantly reduces the 
appearance of breast cancer recurrence. 
 
3.1.6. In human breast carcinomas p70S6K activity is increased by surgery. 
Given the relevance of our findings in the mouse model, we were keen to assess whether these 
data could have a clinical validation. If p70S6K plays a critical role during the early phases of 
recovery after surgery, we could appreciate its activation by assessing p70S6K activity in 
breast cancer specimens taken very close in time from the moment of surgery. Thus, we 
scrutinized p70S6K activity (by immunohistochemical staining of phospho-S6 protein) in 26 
paired breast cancer specimens from patients who undergone lumpectomy first and surgical 
widening to clear surgical margins in a second time (1-2 weeks later). By comparing phospho-
S6 levels, we observed that nearly 50% of patients displayed an increase of p70S6K activity 
in the second specimen respect to the first and only 8% showed a reverse trend, thus strongly 
supporting the hypothesis that p70S6K activity is increased by surgery, also in human tissues 
(Figure 6). 
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Figure 6. Human breast cancer display increased levels of p70S6K activity after surgery. 
Images of immunohistological analysis of phosphorylated S6 expression (pS240/244 S6), in 
samples from two representative breast cancer patients (ductal carcinoma, upper panels and 
lobular carcinoma, lower panels) who underwent second surgery, due to margin positivity. 
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3.1.7. p70S6K activity controls survival of breast cancer cells. 
Results obtained so far suggested that a robust p70S6K signaling was necessary for residual 
isolated cells to survive in the breast microenvironment and to eventually recur. To 
understand the mechanism, we challenged cells to survive in anchorage independence, plating 
them on poly-HEMA coated dishes, and evaluated their survival at different time points. 
TUNEL assay and FACS analysis of active caspase 3/7 were then performed, revealing a 
significant difference in the apoptotic rate anytime p70S6K signaling was tackled (Figure 7A-
B and data not shown). Although an increase in apoptosis was underscored, the use of Tems 
was not as effective as PF (Figure 7A-B and data not shown). Since it is known that 
prolonged treatment with mTOR inhibitors leads to hyper-activation of AKT (76), we tested 
whether failure of Tems treatment in our model could be linked to an AKT-mediated survival 
response. Our results indicated that Tems treatment, initially efficient in dampening p70S6K 
signaling, soon led to AKT hyper-activation (Figure 7C). Conversely, PF maintained its 
inhibition on p70S6K signaling also at longer times, without affecting AKT activation (Figure 
7C). To get more molecular insights, we performed a phosphoproteomic array comparing the 
levels of activation and/or expression of more than 500 proteins in Tems-treated cells respect 
to PF-treated ones. Normalized data confirmed the hyper-activation of AKT and highlighted 
the contextual up-regulation of the pro-survival protein Bcl2 (data not shown). Western Blot 
analysis of cells exposed to increasing doses of Tems uncovered a dose-dependent AKT 
activation, coupled with phosphorylation of its downstream target FOXO3A and up-
regulation of Bcl2 (Figure 7D). These findings prompted us to verify whether these molecular 
events occurred in vivo, as well. We bilaterally injected mouse MFPs with MDA-MB-231 
cells and, when palpable masses appeared, treated tumors for three consecutive days with 
vehicle, PF or two different doses of Tems (6 tumors/treatment). Then, mice were sacrificed 
and tumors analyzed. Also in this context, AKT hyper-activation coupled with Bcl2 up-
regulation were consistently detected in Tems-treated tumors (Figure 7E-G). Notably, staining 
of Bcl2, either by IF or by IHC, highlighted a specific and discrete pattern of expression 
inside the tumor, with agglomerations of Bcl2-positive cells immersed in a Bcl2-negative 
mass. This finding suggested that, under prolonged Tems treatment, isolated cells activated 
asurvival response that could eventually be responsible for the high rate of local relapse 
observed in Tems-treated mice. 
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Figure 7. p70S6K activity controls survival in breast cancer cells.  
A. TUNEL assay of MDA-MB-231 CTR, p70KR cells or treated with the indicated inhibitor 
(PF-4708671 10 µM or Temsirolimus 100 nM), grown in anchorage independence on poly-
HEMA coated dishes for the indicated times. Data are expressed as percent of TUNEL-
positive cells, obtained counting at least 1500 cells/time point/cell type. B. Representative 
images of TUNEL-stained cells, cytospinned on slides after 6 days of anchorage independent 
growth in poly-HEMA coated dishes. C. Western blot analysis of MDA-MB-231 cells grown 
for the indicated times in the presence of the indicated inhibitor. Vinculin expression was used 
as loading control. D. Western blot analysis of MDA-MB-231 cells treated with the indicated 
inhibitor (PF-4708671 10 µM or Temsirolimus 10, 20 and 100 nM) or left untreated. Vinculin 
expression was used as loading control. E. Western blot analysis of lysates derived from 
primary tumor from MDA-MB-231 control cells. Mice were intraperitoneally injected with 
PF-4708671 (50mg/kg i.e. 1200µg/mouse) or Temsirolimus (12.5mg/kg or 25mg/kg  i.e. 
300µg/mouse or 600µg/mouse) or vehicle (Untreated) for three consecutive days and then 
sacrificed. F. Immunofluorescence analysis on tumor sections from experiment described in 
(E), acquired by confocal microscopy. Panels show: immunostaining for pS473 AKT (AF-
488, green), immunostaining for pS473 AKT (AF-488, green) with the nuclear staining with 
propidium iodide (red) and the merge of the immunostaining for Bcl2 (AF-488, green) with 
propidium iodide (red). Bars correspond to 35 µm. G. Immunohistochemistry analysis of Bcl2 
on tumor section from a Tems-treated mouse of the experiment described in (E). Nor 
untreated tumors nor those from PF-treated mice displayed positivity for Bcl2 (magnification 
200x). 
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3.2. Role of STAT3 signaling pathway in breast cancer recurrence 
 
3.2.1. STAT3 is strongly activated upon WF stimulation 
WF are extremely rich in cytokines and growth factors and they have been used throughout 
the in vitro experiments of this project as surrogate source of the inflammatory stimuli present 
in the post-surgical setting in breast microenvironment. Our previous work demonstrated that 
they efficiently stimulated the activation of STAT3 in breast cancer cells, so, first of all, we 
evaluated the activation of STAT3 in a large panel of breast cancer cell lines (Figure 8A-B). 
We confirm that WF strongly activates STAT3 in all the cell lines tested (Figure 8A-B), it is 
evident that 5% WF is able to activate STAT3 at very higher extent than 10% FBS. These 
results suggest that an efficient stimulation of STAT3 is induced particularly in the presence 
of post-surgical fluids, indicating a specific role of STAT3 signaling pathway in this context. 
STAT3 belongs to a family of signal transducers and transcription factors which consist in at 
least seven different members. We evaluated whether other members of STAT family were 
activated upon WF stimulation. Taking advantage of an immunoassay based on the Luminex 
techonology, we detected the activation of several members of STAT family upon WF 
stimulation. As indicated in the table (Figure 8C), this assay confirmed the data obtained by 
western blot: the phosphorylation of Y705 of STAT3 is strongly increased by stimulation of 
BC cells with WF (fold increase: 3.66). Among the other STAT proteins analyzed, only 
STAT1 was efficiently activated, but with a lesser extent respect STAT3. Thus, drainage WF 
strongly stimulate the activation of STAT3. 
 
3.2.2. WF stimulate self-renewal in breast cancer cells 
The signaling pathway of STAT3 is described to be involved in the growth and maintenance 
of tumor initiating cell (TICs) and to be important for self-renewal in breast cancer cells (110-
113). We hypothesized that STAT3 could have an impact in the promotion of the survival and 
proliferation of TICs at the moment of surgical excision, when in the breast 
microenvironment are released factors that activate this pathway. First, we analyze whether 
drainage from breast cancer patients could activate the proliferation and self-renewal of TICs. 
As first approach, we evaluated the presence of side population in MCF-7 cells in the 
presence of WF. Side population is a small population of cells from cancer cell lines enriched 
in TICs, characterized by ability to exclude dyes such as Hoechst. FACS analysis revealed 
that the prolonged presence of WF strongly increase the percentage of side population in this 
cells, from 4.5% to 15.9% (Figure 9A). 
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Figure 8. In breast cancer cell lines, STAT3 is strongly activated following stimulation 
with wound fluids. 
A. Western blot analysis of MDA-MB-468, MDA-MB-231 and MDA-MB-453 cell lines 
serum starved and then stimulated for the indicated times with 10% serum (FBS) or 5% 
wound fluids (WF). B. Same as in (A), but using MCF-7, BT-474 and SK-BR-3 cell lines, as 
indicated. Vinculin expression was used as loading control.C. Table reports the activation of 
five different members of STAT family in MDA-MB-231 cells, following stimulation with 
5% wound fluids for 20 minutes (stimulated) or not (unstimulated). Activation was detected 
using a commercial immunoassay. The value of “fold increase” represents the ratio between 
the unstimulated and stimulated values. 
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Figure 9. WF stimulate proliferation and self-renewal of tumor initiating cells.  
A. FACS analysis evidences side population (SP) in MCF-7 cells growth in complete medium 
(CTR cells) or growth in the presence of wound fluids for 48 hours (WF 5%). SP is identified 
through exclusion of Hoechst dye that is inhibited in the presence of Reserpine. Percentage of 
SP is reported inside the plot. B. Graph reports mammosphere forming efficiency of MDA-
MB-468, MDA-MB-231, BT474 and MCF7 cells. Cells were plated on poly-HEMA coated 
dishes in mammosphere medium (EGF) or without EGF but with the supplement of WF 5%. 
Mammosphere forming efficiency (MFE) was calculated as the ratio between the number of 
mammospheres counted per well and cells seeded per well. C. Same as in A but regarding the 
secondary generation of mammospheres formation. Mammospheres formed in the primary 
generation were collected, digested and replated as single cells in the medium described. D. 
Self-renewal in MDA-MB-468, MDA-MB-231, BT474 and MCF7 cells. Self-renewal was 
calculated as the ratio between the total number of the secondary mammospheres generated 
and the total number of primary mammospheres. In all the cell lines tested, only in the 
presence of WF self-renewal is stimulated. E. Representative pictures show the 
mammospheres formed by MDA-MB-468, MDA-MB-231, BT474 and MCF7 cells in the 
secondary generation. 
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To better characterized the possible role of WF in the stimulation of TICs proliferation and 
self-renewal, we perform the mammosphere assay (Figure 9B-E) that is recognized to be an 
important tool to quantify both stem cell activity and stem cell self-renewal. Stem cell activity 
is calculated from primary mammosphere formation as percentage of mammosphere forming 
efficiency (MFE, the ratio between the number of mammospheres counted per well and cells 
seeded per well), the self-renewal is obtained as the ratio between the total number of 
secondary mammospheres and the total number of primary mammospheres generated (119). 
We tested the ability of several breast cancer cells to form mammospheres plating them in 
standard mammospheres media (with EGF) or in the same media without EGF but with 5% 
WF. Our data indicate that we are able to obtain mammosphere formation in all the cell lines 
tested (Figure 9B-E). The presence of WF increase the MFE comparing with standard 
condition and more importantly the self-renewal is strongly promoted only when WF is 
added. Our results show that WF is able to efficiently stimulate the cancer initiating cells 
activity and self-renewal. 
 
3.2.3. Generation and characterization of breast cancer cell lines with altered STAT3 
activity 
Our data indicate WF are able to strongly stimulate STAT3 activity and to induce breast 
cancer self-renewal. To study the role of STAT3 in the regulation of TICs mediated by WF in 
vitro and in the process of insurgence of local recurrence in vivo, we generated breast cancer 
cell lines with impaired STAT3 activity through different approaches. First, we down-
modulates the activity of STAT3 in two triple negative breast cancer cell lines, MDA-MB-
231 and MDA-MB-468 (Figure 10 and data not shown). We silenced endogenous STAT3 
with anti-human STAT3 sh-RNA and verified the expression/activity of STAT3, especially in 
the presence of WF (Figure 10A and data not shown). STAT3 protein is efficiently silenced 
while the other pathways analyzed were unvaried. Importantly, the activity of STAT3 in the 
silenced clones remains strongly down-modulated respect the control also upon WF 
stimulation (Figure 10A). Then, we better characterized the behavior of STAT3-silenced cell 
lines. First, we stimulated the cells with WF and analyzed the expression of some of the 
STAT3 known target genes. qRT-PCR analysis evidences that, among the target genes 
analyzed, two are specifically down-regulated in sh-clones in the presence of WF, Bcl-2 and 
Survivin (Figure 10B). These results indicate that the survival response could be important for 
breast cancer cells in this context.  
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Figure 10. Activation of STAT3 following WF stimulation is efficiently impaired in 
breast cancer cell lines modified for STAT3 expression. 
A. Western blot analysis of MDA-MB-231 cell line stably transduced with a lentiviral vector 
encoding for control sh-RNA (CTR) or for sh-RNAs directed against human STAT3 (sh), 
serum starved and then stimulated for the indicated times with wound fluids (WF). Vinculin is 
used as loading control. B. qRT-PCR analysis of Bcl-2 and Survivin expression in MDA-MB-
231 CTR cells (sh no Target) or in three different silenced clones (cl#3, cl#9, cl#11). Cells 
were serum starved and then stimulated for the indicated times with wound fluids (WF). C. 
Growth curve analysis of MDA-MB-231 CTR or sh-STAT3 clones. Cells have been seeded 
on day 0, in complete medium (CM) or in the presence of 3% wound fluids (WF), as 
indicated, and then counted by Trypan Blue exclusion test, every day for 5 days. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
46 
 
The clones obtained were tested also in more functional assay. We analyzed the effects of 
alteration of STAT3 activity in the proliferative behavior of cells through growth curve assay. 
The proliferation rate of silenced cells is slightly decreased respect the control cells(Figure 
10C). This is more evident when cells are cultured in the presence of 3% WF, suggesting that 
STAT3 activity could be more important in the regulation of breast cancer cells behavior 
when stimulated with inflammatory fluids (Figure 10C). 
As second approach, we impaired STAT3 activity through the use of several different 
commercially available chemical inhibitors. We chose to use four inhibitors, differing for 
their mechanism of action: S3I-201, Stattic and STA-21 are non-peptidic inhibitors targeting 
SH2 domain and Galiellalactone, targeting the DNA binding domain. To obtain the inhibition 
of STAT3 activity and to avoid tossicity of the chemical compounds, we first set up the 
optimal concentration and the time of treatment for each  cell line. We performed differential 
separation of cytoplasmic and nuclear fraction to analyze the activity and nuclear 
translocation of STAT3 in the presence or not of the inhibitors (Figure 11A). S3I-201, Stattic 
and STA-21 are described to target the SH2 domain of STAT3, thus preventing its nuclear 
translocation. From western blot analysis we could appreciate that S3I-201, Stattic and STA-
21 were able to inhibit the shuttling of STAT3 from cytoplasm to nucleus after WF 
stimulation. STA-21 and S3I partially affect the expression of Cyclin D1, one of the targets of 
STAT3 (Figure 11A). Regarding the effect of Galiellalactone, as expected, the translocation 
of STAT3 in the nucleus was not affected (Figure 11A). We evaluated also whether the 
inhibitors used impaired the expression of STAT3 target genes, at RNA level. In MDA-MB-
468 cells all inhibitors were quite effective in decreasing the expression of Bcl-2, Survivin 
and Cyc D1 (Figure 11B). In MDA-MB-231 cells the effect of the different compounds on the 
expression of these genes although present was less evident (Figure 11B). Our data show that 
S3I, Stattic and STA-21 were quite effective in preventing the translocation in the nucleus and 
the activation of STAT3 in both the cell lines. Galiellalactone seemed to be more efficacious 
in MDA MD 468 cells where it inhibited all target genes analyzed.  
 
3.2.4. Inhibition of STAT3 impairs mammosphere formation and self-renewal. 
Our experiments indicate that WF induce mammospheres formation and increase self-renewal 
in breast cancer cells (Figure 9). Since it is well established that STAT3 is involved in the 
maintenance of stem-like properties of breast cancer cells, we hypothesized that STAT3 could 
be a mediator of TICs properties induced by WF. To evaluate this possibility, we performed 
mammosphere assay plating the cells with medium containing 5% WF, in the presence or  
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Figure 11. Activation of STAT3 following WF stimulation is efficiently impaired in 
breast cancer cell lines inhibited for its activity. 
A. Western blot analysis of cytoplasmic and nuclear fraction in MDA-MB-231 cell line 
treated with STA-21 (30µM for 48h), Galiellalactone (12µM for 3h), S3I-201 (50µM for 24h) 
and Stattic (10µM for 3h) or left untreated and stimulated for 20 minutes with 5% WF. 
Tubulin is used as cytoplasmic marker, fibrillarin as nuclear marker. B. qRT-PCR analysis of 
Bcl-2, Survivin and Cyclin D1 expression in MDA-MB-231 and MDA-MB-468 treated with 
STA-21, Galiellalactone, S3I-201 and Stattic or left untreated. 
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absence of the inhibitors previously characterized. In order to have multiple approaches and to 
have more robust results, we used all the compounds previously tested. All inhibitors had a 
strong effect in preventing the formation of mammospheres in all tested breast cancer cell 
lines (Figure 12A-D). In particular, we observed a dramatic effect in MDA-MB-468 cells, 
where the ability to form mammospheres is very high (MFE in WF: 7%). Not only the 
number but also the size of the mammospheres was affected (Figure 12C-D). Stattic inhibitor 
completely prevented the formation of mammospheres but we hypothesize a toxic effect of 
the compound in this context (Figure 12A-D). As additional approach, we used a blocking 
antibody for IL6, a cytokine known to activate STAT3 signaling pathway. The analysis of the 
mammospheres forming efficiency (MFE) value pointed out that the action of the blocking 
antibody only slightly impaired the formation of mammospheres in the cell lines tested, 
suggesting that blocking a single agent was not sufficient to inhibit the activation of STAT3 
signaling in a medium rich of cytokines and growth factors such as WF (Figure 12A-D).  
Then, we evaluated whether STAT3 activity in the presence of WF could be fundamental also 
in the process of self-renewal of cancer stem cells. Secondary generation of mammospheres 
could not be plated from cells derived from primary generation grown in the presence of 
inhibitors, due to the paucity and lower vitality of the mammospheres. So, we decided to plate 
the first generation in medium containing WF but without inhibitors that were added only in 
the secondary generation. Importantly, the graph show that the self-renewal of MDA-MB-468 
cells is strongly affected by the inhibitors, supporting that STAT3 plays an important role in 
the promotion of renewal of TICs (Figure 12E).  
Altogether, these data evidenced that WF strongly stimulated mammosphere formation and 
self-renewal of breast cancer cells and this is mediated, at least in part, by STAT3 . 
 
3.2.5. STAT3 activity positively impacts on tumor take rate, in vivo 
Once characterized the effects of inhibition of STAT3 in proliferation and mammosphere 
formation, in vitro, we moved to in vivo models. First of all, we evaluated whether the down-
modulation of STAT3 activity could have a role in the initiation of primary tumors formation, 
in nude mice. We injected in mouse mammary fat pads decreasing number of MDA-MB-
231control (CTR) cells and two different clones silenced for STAT3, using Matrigel to 
support their initial survival and waited for the appearance of tumor masses (Figure 13A-B). 
The take rate of CTR cells was 100%, injecting 2x105, 1x105 and 5x104 cells while the 
behavior of the clones silenced for STAT3 was slightly different. One of the clones tested  
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Figure 12. Inhibition of STAT3 impacts on maintenance and self-renewal of tumor 
initiating cells. 
A. Graph reports mammosphere forming efficiency of MDA-MB-468 cells. Cells were plated 
on poly-HEMA coated dishes in mammosphere medium with the supplement of WF 5% in 
the presence or not of the indicated inhibitors(anti-IL6 0.2µg/ml, S3I-201 100µM, Stattic 
10µM, STA-21 30µM and Galiellalactone 25µM). Mammosphere forming efficiency (MFE) 
was calculated as the ratio between the number of mammospheres counted per well and cells 
seeded per well. B. Same as in A but in MDA-MB-231 cells (anti-IL6 0.2µg/ml, S3I-201 
50µM, Stattic 10µM, STA-21 30µM, Galiellalactone 12µM). C. Pictures show the 
mammospheres formed by MDA-MB-468 in the presence of STAT3 inhibitors. D. Same as in 
(C) but regarding MDA MD 231 cells. E. Graph reports self-renewal in MDA-MB-468 cells 
in the presence of the compounds indicated. Self-renewal was calculated as the ratio between 
the total number of the secondary mammospheres generated and the total number of primary 
mammospheres. Primary generation was obtained plating the cells on poly-HEMA coated 
dishes in mammosphere medium containing WF without the inhibitors. After the formation of 
mammospheres, cells were collected, digested and re-plated to form secondary 
mammospheres adding the inhibitors in the medium. 
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showed a decreased take rate but the other one, despite with a delay respect the CTR cells, 
showed a 100% take rate (Figure 13A). To evaluate more in detail these differences and to 
understand if it was a specific effect of STAT3 in the initiation of the tumors, we decided to 
inject lower numbers of cells to obtain a more stringent condition. Injecting 2x104 and 1x104, 
it is evident that imparing STAT3 activity strongly impacted on the tumor growth initiation 
(Figure 13A-B). At 2x104 and 1x104 cells, CTRs present a take rate of 88% and 50% 
respectively, while no tumor was formed by one of the 2 clones and only one tumor by the 
second clone (Figure 13A-B). 
In conclusion, these data demonstrate that STAT3 activity positively impact on the initiation 
of breast tumorigenesis.  
 
3.2.6. Role of STAT3 activity in the control of locoregional recurrence, in vivo 
Our data suggested that STAT3 regulate TICs maintenance and self-renewal in the presence 
of WF and it is known that this population of cells is important for tumor recurrence. In order 
to evaluate the role of STAT3 in breast cancer local recurrence formation, we utilized an 
experimental model in vivo, already set up and characterized in our lab (Figure 5A). Since we 
know that primary tumors with impaired STAT3 grew less than the control (data not shown), 
we injected 1x106 of MDA-MB-231 CTRs cells and 2x106 of MDA-MB-231 sh-STAT3 
clones, to obtain similar primary masses at the time of surgery. The picture in Figure 13C 
shows that the masses were very similar among the groups at the day of the surgery. These in 
vivo experiments are currently under evaluation. We monitor the appearance of local 
recurrence during a period of at least eight weeks. The data obtained so far (5 weeks) show 
STAT3 silencing decreased the number or recurrence formation from 56% in control mice to 
25% for sh#9 and sh#11 (Figure 13D-E). The disease free survival at 5 weeks is positively 
affected by the inhibition of STAT3 activity (Figure 13E). However, long-term follow up is 
currently under way, to evaluate which is the actual involvement of STAT3 in the regulation 
of the processes that lead to local relapse. 
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Figure 13. Impaired STAT3 activity decreases tumor take rate and recurrence 
formation in a mouse model of breast cancer. 
A. Tumor take-rate assessed by injection of the indicated numbers of MDA-MB-231 CTR or 
sh-STAT3 clones, in the presence of Matrigel. B.Graph reports the disease free survival in the 
indicated cohorts of mice, after injection of decreasing number of MDA-MB-231 CTR or two 
different sh-STAT3 clones. Data are reported as percentage of mice that developed primary 
tumors during the 7 weeks of follow up.C. Figures show an example of primary masses 
excised from nude mice after surgery. It is evidenced the similar dimension of the tumors in 
the different groups. D. Table reports the percentage of local recurrences formed by mice 
injected with CTR cells or two different clones of sh-STAT3 after 5 weeks of follow up. 
Long-term follow up is currently in progress. E. Graph reports the disease free survival in the 
indicated cohorts of mice, after removal of the primary tumor. Data are reported as percentage 
of mice that developed recurrent disease during the 5 weeks of follow up. Long-term follow 
up is currently in progress. 
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Local relapse in EBC patients strongly influences disease outcome (11) and represents a 
common and unfavorable prognostic event. The preferential localization of breast cancer 
recurrences at the surgical scar site has not yet been adequately explained, and various 
hypotheses have been generated. The most common explanation is the presence of ‘‘residual’’ 
tumor cells after the surgical excision. However, this cannot be the unique reason. The 
possible deleterious effects of surgical wounding have been speculated for a long time and 
have been shown in mice (25,32). Also in humans, it was demonstrated that the growth 
kinetics of breast cancer micro metastasis is modified by surgery, representing a perturbing 
factor in the process of relapse or metastasis development (26, 31). Moreover, experimental 
and clinical observations suggest that the extent of surgery may represent a variable able to 
enhance tumor burden (24-26, 28, 121). A recent clinical study comparing radical mastectomy 
with breast conserving surgery reported that after extensive mastectomy, an excessive wound 
response during the healing process might stimulate the secretion of as-yet uncharacterized 
growth factor(s) that precipitates loco-regional recurrence (21). So, surgery and the 
consequent inflammatory response caused by wounding could be a factor that favors the 
proliferation of “residual” tumor cells. The communication between microenvironment and 
tumor cells plays an important role in this context. Normally, the microenvironment 
surrounding the tumor provides tumor-suppressive signals; however, once tissue homeostasis 
is lost, the altered microenvironment can itself become a potent tumor promoter, as amply 
demonstrated in recent research (121). The process of wound healing can provoke changes in 
the surrounding and shift the balance between tumor-suppressive and tumor-promoting 
signals. The combination of inflammation, growth factors produced in the microenvironment 
and other tissue-associated promotional forces can breach the barrier, resulting in promotion 
of the growth of residual cells into a tumor.  
Interestingly, wound axillary fluids harvested from breast cancer patients have been proved to 
stimulate Her2-positive mammary carcinoma cell growth, an effect that could be only 
partially abrogated by impairing Her2 signal transduction (34). Accordingly, our previous 
work not only reveals that several growth factors and cytokines secreted in the WF participate 
in the stimulation of mammary carcinoma cells but also represents the first formal 
demonstration that WF harvested from breast cancer patients who have undergone wide local 
tumor excision stimulate breast cancer cell motility, invasion, and growth in three-
dimensional contexts (33). In the same work we demonstrated that one single application of 
TARGeted Intraoperative RadioTherapy (TARGIT) almost completely abrogates the 
stimulatory effects of surgical WF on cancer cells in vitro, suggesting that it may confer more 
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benefits than those expected from the tumoricidal effect of radiotherapy (33). The beneficial 
effect of TARGIT could be attributed not only to a better cell killing but also by modifying 
the wound microenvironment. In support to this hypothesis the recent results of randomized 
trial TARGIT-A confirmed non-inferiority respect EBRT only when TARGIT was delivered 
concurrently with lumpectomy (prepathology stratum) but not in the postpathology stratum 
(35). Several factors might have played a part in achieving the low recurrence rates that was 
identified in the stratum randomized to receive TARGIT immediately after lumpectomy. 
These factors certainly include the immediate delivery of radiation to tissues, which appears 
to be essential to achieve the beneficial effects on the tumor microenvironment, suggesting 
that the timing of treatment is an important variable that can determine different clinical 
response (35). TARGIT significantly modifies the protein expression profile of the WF and 
the activation of p70S6 kinase and STAT3 pathways on stimulation of breast cancer cells 
(33). 
In this work, we explore the role of p70S6K and STAT3 in the response to WF stimulation 
and in the process of breast cancer local recurrence. Many data suggest that p70S6K plays a 
pivotal role during breast cancer progression (33, 66-68, 70). Here, using a mouse model of 
EBC we show that interfering with p70S6K activity had a significant impact on breast cancer 
cell behavior and almost completely prevented formation of local recurrence. Importantly, a 
three-day schedule of peri-operative treatment with specific the p70S6K1 inhibitor PF-
4708671 was sufficient to significantly prevent the appearance of relapses and our data 
demonstrate that this critical event takes place in very narrow window of the disease. Our data 
demonstrate that survival, more than proliferation, of residual isolated breast cancer cells 
requires the activity of p70S6K1. In accord with our data, a recent report demonstrated that 
p70S6K knock-down prevents lung metastasis in a breast cancer xenograft model (122), 
supporting that p70S6K is required for breast cancer cell settlement and survival. Inhibition of 
mTOR by Temsirolimus should, in principle, elicit the same response but our experiments 
clearly demonstrate that this is not the case. First, Tems did not induce a reduction of local 
recurrence rate in our mouse model of breast cancer. Then, Tems was not able to induce 
apoptosis in cells challenged to grow in anchorage independence. Finally, at molecular level, 
treatment with Tems blocked the p70S6K negative feedback loop, leading to activation of 
AKT and up-regulation of Bcl2, which, in turn, fostered cell survival. The activity of p70S6K 
is regulated by a wide range of extracellular signals and by multiple pathways (43,50). 
Although mTOR is the principal regulator of p70S6K, it is well documented that cooperation 
of upstream molecules is important for full activation and functionality of p70S6K (55, 123, 
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124) and targeting different nodes of the same pathway may result in dramatically different 
ability to block or promote a certain phenotype. This is strongly supported by our data 
showing that increasing doses of PF reduced recurrence formation, while increasing doses of 
Tems rather stimulated them. Very recent studies corroborate our finding. A kinome-wide 
drug profiling using a Drosophila model of multiple endocrine neoplasia type 2A, 
demonstrated that inhibition of S6K was required for optimal animal survival, whereas 
inhibition of Tor led to toxicity owing to release of negative feedback (125). In advanced 
prostate cancer, allosteric inhibition of mTOR by rapamycin was proved unable to achieve 
any therapeutic benefit (126), resulting in ineffective block of the translation of specific pro-
invasion messenger RNAs, specifically mediated by its effector 4EBP1 and not p70S6K 
(126). In EBC, it is mandatory to restrain local recurrence (127, 128) because this will lead to 
one life saved every four recurrences prevented (11). In this context, targeting the pro-survival 
activity of mTOR by hampering p70S6K1 activity is necessary to cause breast cancer cell 
apoptosis and almost completely prevent cancer relapse. 
STAT3 is inappropriately activated in a vast percentage of breast tumors but its concrete role 
in breast cancer initiation and/or progression is still very controversial. Here, we show that 
STAT3 was strongly activated when breast cancer cells were exposed to wound fluids (WF) 
drained from EBC patients, an experimental condition that partially contains and recapitulates 
in vitro the microenvironment surrounding cancer cells in vivo, following surgery. For the 
first time, we have shown here that prolonged stimulation with post-surgical fluids induces 
not only growth and invasion, but also the proliferation and self-renewal of breast cancer cells 
with phenotypes of tumor initiating cells. Our data indicate that in this process STAT3 
signaling seems to be strongly involved. It is already known that STAT3 is an important 
regulator of tumor initiating cells that are known to be responsible for insurgence of cancer 
recurrences (108-113). By inhibiting STAT3 through different compounds, mammospheres 
formation induced by WF stimulation was strongly impaired; the same results were not 
achieved using an antibody able to block IL-6 signaling. WF is composed by a wide spectrum 
of cytokines and growth factors that are able to activate survival and proliferation by different 
intracellular signaling cascades. STAT3 pathway is certainly one of these cascades and its 
activation impinges on the TICs growth and maintenance. In accord with our results, other 
studies have shown that STAT3 is involved in regulation of TICs (108-113). Here, we not 
only confirmed these findings in our model system but we show that one of the possible effect 
of surgery on tumor cells is to increase “stemness properties” of breast cancer cells and that 
blocking STAT3 in this context could represent an exploitable strategy. The relevance of our 
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results in vitro, was confirmed by our results in vivo. The impairment of STAT3 pathway 
largely influenced the take rate ability of breast cancer cells in mouse MFP, especially when 
low numbers of cells were injected. It is known that STAT3 signaling is involved in inducing 
and maintaining a pro-carcinogenic inflammatory microenvironment (78). In line with this, 
inflammatory fluid produced after surgical excision activates STAT3 that induce proliferation 
of cells, leading to the appearance of local recurrence. Many of the downstream target genes 
of STAT3 encode cytokines and growth factors, the receptors of which signal through the 
same STAT3, thereby providing a mechanism for autocrine and paracrine STAT3 activation 
(78, 85, 88-90). It is possible that the activation of STAT3 by WF triggers a positive feedback 
loop that, not only activate the survival and proliferation of residual tumor cells but also 
activate the cells of the surrounding microenvironment, breaking the tissue homeostasis. It 
was shown that transient activation of Src can mediate a switch from immortalized breast 
cells to a stably transformed line that forms self-renewing mammospheres (129). This 
activation triggers a positive feedback loop mediated also by STAT3 that maintains the 
transformed state also in the absence of inducing signal. We can speculate that in our system, 
STAT3 activation could be a signal able to induce the transformation or the re-activation of 
cells that in absence of perturbing factors, such as surgery, will be dormant. The results 
obtained in vitro, prompt us to hypothesize that STAT3 could act specifically on tumor 
initiating cells, increasing the proliferation and the self-renewal ability already acquired or 
could stabilize cancer stem cell phenotype in residual cells. This possibility needs to be 
further explored and more time and experiments are now in progress to establish whether the 
specific inhibition of STAT3 could effectively represent a promising tool to restrain local 
recurrence. 
The act of surgery leads to a profound modification of the local microenvironment. In that 
occasion reactive microenvironment is able to sustain the survival and, eventually, the re-
growth of residual cancer cells through the secretion of inflammatory cytokines and growth 
factors. Altogether, our results allow to suggest that in this context two signaling pathways 
strongly influence the response of residual tumor cells. The activation of p70S6K1 prevalently 
impinges on the survival of these cells, while the activation of STAT3 stimulates the self-
renewal ability of tumor initiating cells,which, we demonstrated here,is strongly promoted by 
WF. We can hypothesize that these pathways could cooperate to allow the growth of residual 
cells in this specific setting, to lead the formation of local relapse. Taken together, our 
findings provide a biological rationale for the use of molecularly targeted agents to 
compensate the harmful consequences of surgery and wound healing process. It is well 
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recognized that improved clinical efficacy of radiotherapy would make a substantive impact 
in clinical practice and patient outcomes (130). The use of peri-operative treatment with 
targeted agents in combination with intraoperative radiotherapy could improve the clinical 
response in EBC patients through the “sterilization” of microenvironment and the inhibition 
of the pathway mainly involved such as p70S6K and STAT3. The combination of treatments 
coupled with the correct timing of administration could strongly improve the patient response 
thus providing new therapeutic options also for the less responsive subtypes. 
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5.1. Study approval 
All animal experiments were reviewed and approved by the CRO Institutional Animal Care 
and Use Committee and were conducted according to that committee’s guidelines. 
Paraffin-embedded human breast cancer samples were obtained from the Università degli 
Studi di Roma La Sapienza, Azienda Ospedaliera Sant'Andrea, Rome, Italy. 
Wound Fluids (WF) were collected at Centro di Riferimento Oncologico, Aviano, Italy. 
Scientific use of biological material was approved by Ethics Committee of the Centro di 
Riferimento Oncologico, Aviano, and of Università degli Studi di Roma La Sapienza, Rome, 
Italy. Specific informed consent was obtained from all patients. 
 
5.2. Cell culture and development of stable cell lines 
MDA-MB-231 (basal, ER-, PR-, HER2-), MDA-MB-453 (luminal, ER-, PR-, HER2-), MDA-
MB-468 (basal, ER-, PR-, HER2-), MCF-7 (luminal, ER+, PR+, HER2-), BT-474 (luminal, 
ER-, PR-, HER2+), BT-549 (basal, ER-, PR-, HER2-), HBL-100 (basal, ER-, PR-, HER2-) 
and SK-BR-3 (luminal, ER-, PR-, HER2+) mammary carcinoma cell lines (131) were 
obtained from ATCC (LGC Standards) and grown in Dulbecco modified Eagle medium 
(DMEM, Lonza) supplemented with 10% fetal bovine serum (FBS, SIGMA). Stable cell 
clones were obtained by retroviral transduction with a vector carrying Puromycin resistance 
(murine stem cell virus retroviral vectors, MSCV; Clontech), following the manufacturer's 
instructions, subcloned to encode for kinase inactive mutant HA-p70S6K-KR (carrying the 
substitution K100R) (117). The vector has been kindly provided by John Blenis (Harvard 
Medical School, Boston). p70S6K and STAT3-silenced mammary carcinoma cells were 
generated by lentiviral transduction of pLKO vectors encoding for human shRNAs of the 
MISSiON system (pLKO sh-p70S6K1: sh1_TRCN0000194766, sh2_TRCN0000003159, 
sh3_TRCN0000003162; pLKO sh-STAT3: sh2_TRCN0000020842, 
sh3_TRCN0000020843). All cell lines were authenticated by BMR Genomics srl Padova, 
Italia, on January 2012 according to Cell ID TM System (Promega) protocol and using 
Genemapper ID Ver 3.2.1, to identify DNA STR profiles. 
 
5.3. Preparation of protein lysates and immunoblotting analysis 
MDA-MB-231, MDA-MB-453, MDA-MB-468, MCF-7, BT-474, BT-549, HBL-100 and SK-
BR-3 mammary carcinoma cell lines were serum starved in DMEM containing 0.1% bovine 
serum albumin (BSA, SIGMA) and then stimulated with 10% FBS or 5% WF for the 
indicated time points. Where indicated, cells were also pre-treated for 30 minutes or for 
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longer times (as indicated) with the following inhibitors: PF-4708671 (p70S6K1 inhibitor, 10 
µM, SIGMA) and Temsirolimus (Rapamycin analogue, 10, 20, 100 nM, Wyeth). 
To extract total proteins cells were scraped on ice using cold NP40 lysis buffer (0.5% NP40; 
50 mM HEPES pH 7; 250 mM NaCl; 5 mM EDTA; 0.5 mM EGTA, pH 8) plus a protease 
inhibitor cocktail (Complete™, Roche) and supplemented with 1 mM Na3VO4 (SIGMA), 10 
mM NaF (SIGMA) and 1 mM DTT (SIGMA).  
To extract total proteins from tumor specimens, the same procedure was used, except that 
tissue disruption was first achieved by using the TissueLyser II (Qiagen).  
For immunoblotting analysis, proteins were separated in 4-20% SDS-PAGE (Criterion 
Precast Gel, Biorad) and transferred to nitrocellulose membranes (GE Healthcare). 
Membranes were blocked with 5% dried milk in TBS-0.1% Tween20 or in Odyssey Blocking 
Buffer (Licor, Biosciences) and incubated at 4°C overnight with primary antibodies. Then, 
membranes were incubated 1 hour at RT with horseradish peroxidase-conjugated secondary 
antibody (GE Healthcare) for ECL detection (GE Healthcare) or with IR-conjugated (Alexa 
Fluor 680, Invitrogen or IRDye 800, Rockland) secondary antibodies for infrared detection 
(Odyssey Infrared Detection System, Licor). 
Primary antibodies AKT (sc-1618), ERK1 (sc-94), p70S6K1 (sc-8418), STAT3 (sc-482), 
Fibrillarin (sc-25397) and Vinculin (sc-7694) were purchased from Santa Cruz; pT202/204 
ERK1/2 (#9101), pS473 AKT (#4060), pT389 p70S6K1 (#9234), S6 (#2217), pS235/236 S6 
(#4858), pS240/244 S6 (#5364), pT37/46 4EBP1 (#2855), 4EBP1 (#9644), pT32 FOXO3a 
(#9464), pY705STAT3 (#9131) were purchased from Cell Signaling; Actin (#A5060) and 
Tubulin (T9026) was purchased from SIGMA; HA (#PRB101C) was purchased from 
Covance; Bcl2 (#OP60) was purchased from Calbiochem; Cyclin D1 (#04-1151) was 
purchased from Millipore. 
 
5.4. Separation of nuclear and cytoplasmic fraction 
MDA-MB-231 and MDA-MB-468 mammary carcinoma cell lines were serum starved in 
DMEM containing 0.1% bovine serum albumin (BSA, SIGMA) and then stimulated with 5% 
WF for the indicated time points. Where indicated, cells were pre-treated with the following 
inhibitors: STAT3 inhibitor VI S3I-20 (Santa Cruz; MDA-MB-231: 50µM with pre-treatment 
of 24h, MDA-MB-468: 100µM with pre-treatment of 24h), STA-21 (Santa Cruz; MDA-MB-
231: 30µM with pre-treatment of 48h, MDA-MB-468: 30µM with pre-treatment of 48h), 
STAT3 inhibitor V Stattic (Santa Cruz; MDA-MB-231: 10µM with pre-treatment of 3h, 
MDA-MB-468: 10µM with pre-treatment of 16h) and Galiellalactone (Santa Cruz; MDA-
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MB-231: 12 µM with pre-treatment of 3h, MDA-MB-468: 25 µM with pre-treatment of 24h). 
To perform the differential extraction of cytoplasmic and nuclear proteins, cells were 
resuspended in Buffer A (10 mM HEPES pH 7.9, 0.1 mM EDTA pH 8, 0.1 mM EGTA pH 8, 
10 mM KCl) plus all the previously described inhibitors. Samples were kept on ice for 15 
minutes, after that 0.5% NP40 was added and samples were centrifuged at 6000 rpm for 1 
minute at 4°C. The supernatant, representing the cytoplasmic protein fraction, was collected. 
After three washes in Wash Buffer (0.32M sucrose, 3mM CaCl2, 2mM Mg-Acetate, 0.1mM 
EDTA, 10mM Tris HCl pH8, 0.5% NP40), pellets were digested in Buffer C (20 mM HEPES 
pH 7.9, 1 mM EDTA pH 8, 1 mM EGTA pH 8, 400 mM NaCl, plus all the inhibitors) and 
incubated on ice for 20 minutes. Samples were then centrifuged at max speed for 15 minutes 
at 4°C to recover the supernatant, representing the nuclear protein fraction. 
 
5.5. Wound fluid collection 
Drainage Wound Fluids (WF) were collected over the 24h after surgery from unselected 
patients undergone breast-conserving surgery, as described previously (33). The assays were 
then performed using pools of all fluids. 
 
5.6. Histological analysis and immunohistochemistry 
Mouse samples were fixed in formalin (over night at 4°C) and processed for standard paraffin 
embedding. Histological sections (5µm thick) were made from the paraffin blocks, 
deparaffinated with xylene, and stained with haematoxylin and eosin. 
For human breast cancer specimens, routine deparaffinization of all sections mounted on 
positive charge slides was carried out according to standard procedures, followed by 
rehydration through serial ethanol treatments.  Slides were immersed in citrate buffer [0.01M 
sodium citrate (pH 6.0)] and heated in a microwave oven at 600W (three times for 5 min 
each) to enhance antigen retrieval. Endogenous peroxidase was blocked with 0.3% hydrogen 
peroxide in methanol for 30 min.  Sections were immunostained for 1hr at room temperature 
with two different clones of anti-pS6 (#4858, #5364, Cell Signaling) or of Bcl2 (#OP60, 
Calbiochem). The primary antibody was omitted and replaced with preimmune serum in the 
negative control. Sections were reacted with biotinylated anti-rabbit antibody and 
streptavidin-biotin-peroxidase (Histostain-SP Kit, Zymed Laboratories, San Francisco, CA).  
Diaminobenzidine was used as a chromogene substrate.  Finally, sections were washed in 
distilled water and weakly counterstained with Harry's modified haematoxylin. 
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5.7. Immunofluorescence analysis 
Fresh mouse tumor specimens were included in OCT and stored at -80°C. Histological 
sections (5µm thick) were made from the OCT blocks and fixed 20’ at RT in 4% PFA before 
blocking in 10% normal goat serum. Sections were immunoprobed at 4°C O.N. with anti-
pS473AKT (#4060, Cell Signaling) or of Bcl2 (#OP60, Calbiochem) primary antibodies. The 
primary antibody was omitted and replaced with preimmune serum for the negative control. 
Sections were then probed with AlexaFluor-488-conjugated secondary anti-rabbit (Invitrogen) 
for 1h at RT, followed by nuclear staining with propidium iodide for 20’ at RT. Stained 
sections were then observed using a confocal laser-scanning microscope (TSP2 Leica) 
interfaced with a Leica DMIRE2 fluorescent microscope. 
 
5.8. Proliferation assays 
For growth curve, 5-9 x 104 cells/well (depending on the cell type) were seeded in 6-well 
plates in complete medium or in serum free medium supplemented with 3% WF (SFM-3% 
WF), in triplicate. Where indicated, PF-4708671 (p70S6K1 inhibitor, SIGMA) or 
Temsirolimus (Rapamycin analogue, Wyeth) were added in the medium at the concentration 
indicated. Fresh medium, with or without inhibitors, was added every other day. At the 
indicated times, cells were detached by trypsin-EDTA and counted by Trypan Blue exclusion 
test. 
To evaluate the anchorage-independent cell growth, MDA-MB-453 cells (1.5x104) were re-
suspended in 2 ml top agar medium (DMEM-10% FBS or SFM-3% WF, 0.4% Low Melting 
Agarose, SIGMA) and quickly overlaid on a previously gelified 0.6% bottom agar medium 
(DMEM-10% FBS, 0.6% LowMelting Agarose, SIGMA). The experiments were performed 
in six-well tissue culture plates, in triplicate. Fresh medium was added to the wells twice a 
week as a feeder layer.  After three weeks, the number of colonies was counted in 10 
randomly chosen fields, at 10X magnification. 
 
5.9. Motility assays 
For invasion experiments, HTS Fluoroblok transwells were coated overnight at 4°C with a 
layer of Matrigel (6µg, Cultrex BME) diluted inDMEM 0.1% BSA. Cells were labeled with 
DiI fluorescent vital dye (MolecularProbes) for 20 minutes at 37°C and plating 1x105 cells in 
the upper chamber of transwell-like inserts, carrying a fluorescence-shielding porous 
polyethylene terephthalate membrane with 8 µm pores (HTS Fluoroblok, BD) and then 
incubated at 37°C for the an overnight. The lower chamber was filled with serum free 
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medium supplemented with 5% WF plus PF-4708671 (10 µM) or Temsirolimus (100 nM), as 
indicated.  
For evasion assay, 7.5x103 cells were included in Matrigel (Cultrex, BME) drops at the final 
concentration of 6 mg/ml (12µl of matrix volume per drops). Matrigel was diluted in DMEM 
0.1% BSA. The drops, sufficiently spaced from one another, were dispensed in cell culture 
dishes and maintained for 1 h at 37°C upside down to let jellify. Then, the dishes were turned 
up and the drops incubated in complete medium or serum free medium supplemented with 5% 
WF. The evasion ability was evaluated 6 days after inclusion by measuring the distance 
covered by crystal violet-stained cells exited from the drops (5 drops/cell lines/experiment). 
Images were collected using a stereo microscope Leica M205FA. 
 
5.10. RNA extraction, RT-PCR and qRT-PCR 
RNA from mouse samples (primary tumors and recurrences) or from cells was extracted using 
TRIzol (Invitrogen). Disruption of the tissue sample was achieved by grinding the frozen 
tissue using the TissueLyser II (Qiagen). Complete homogenization was achieved by passing 
the lysate at least 5 times through a 23-gauge needle fitted to an RNase-free syringe. RNA 
was then quantified and retro-transcribed with AMV Reverse Transcriptase (according to 
provider’s instruction, Promega) to obtain cDNAs. The obtained cDNAs were amplified by 
PCR in order to confirm the presence in the recurrences of the same cell injected. The 
following primers designed on vectors were used:  
pMSCV FW, 5’-CCCTTGAACCTCCTCGTTCGACC-3’;  
pMSCV RW, 5’GAGACGTGCTACTTCCATTTGTC-3’.  
Absolute expression of human Bcl-2, Survivin and Cyclin D1 was evaluated by qRT-PCR 
using SYBR Green dye-containing reaction buffer (Experteam). The primers (SIGMA) used 
were:  
human Bcl-2 FW, 5-TCCGATCAGGAAGGCTAGAGTT-3’;  
human Bcl-2 RW, 5’-CGGTCTCCTAAAAGCAGGC-3’  
human Survivin FW: 5’-CCACCGCATCTCTACATTCA-3’  
human Survivin RW: 5’-TATGTTCCTCTATGGGGTCG-3’ 
human Cyclin D1 FW: 5’-AGAAGGAGGTCCTGCCGTCC-3’ 
human Cyclin D1 RW: 5’-GGTCCAGGTAGTTCATGGCC-3’  
Standard curves (10-fold dilution from 101 to 10-4 attomoles) were prepared both for target 
genes and for housekeeping genes. The incorporation of the SYBR Green dye into the PCR 
products was monitored in real time using the iQ5 Biorad real-time PCR detection system, 
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and the resulting threshold cycles (Ct) were computed. Ct values were converted into 
attomoles and the normalized target gene value was obtained by using at least two different 
housekeeping genes. 
 
5.11. Apoptosis assays 
To evaluate cell survival in adhesion-independent growth, cell attachment was prevented by 
coating Petri dishes with 12mg/ml Poly-HEMA in 95% ethanol (poly-2-hydroxyethyl 
methacrylate, SIGMA). MDA-MB-231 cells were plated in Poly-HEMA coated dishes in 
serum free medium and cultured for the indicated time points. Where indicated, PF-4708671 
and Temsirolimus were added to the medium at the final concentration of 10 µM or 100 nM, 
respectively. Apoptosis was subsequently measured by TUNEL assay: 3x104 cells were 
washed in PBS and cytospinned on a glass slide, (Shandon Cytospin 4, Thermo Scientific). 
Detection of apoptosis was performed using In Situ Cell Death Detection Kit, AP (Roche), 
according to the manufacturer’s instructions. Apoptotic rate was calculated as the ratio of 
positive cells over the total number/field. Images were acquired using Leica fluorescence 
microscope (DMI6000B) equipped with a 20X objective. 
 
5.12. Side population analysis 
To identify side population, MCF-7 cells were resuspended in DMEM containing 2%FBS and 
10mM HEPES at 1x106 cells/ml in the presence or not of ABC transporter inhibitor, 
Reserpine (Sigma, 50µM) and were incubated for 5 minutes at 37°C. After, cells were 
incubated with Hoechst 33342 (Sigma, 5µg/ml) for 90 minutes at 37°C. After staining, the 
cells were washed in wash buffer (HBSS containing 2%FBS and 10mM HEPES) and were 
centrifuged for 7 minutes at 1200 rpm. Cells were resuspended in 200 µl of wash buffer and 
7-AAD (2 µg/ml) was added for 10 minutes before FACS analysis, which allows the 
discrimination of dead versus live cells. Analyses sorting were done on a FACS LSRFortessa 
(Becton Dickinson). The Hoechst 33342 dye was excited at 357 nm and its fluorescence was 
dual-wavelength analyzed (blue, 402–446 nm; red, 650–670 nm). 
 
5.13. Mammospheres Assay 
To establish primary mammospheres, cells were plated in poly-HEMA coated dishes as single 
cell suspension (6000 cells in 35 mm dishes). Standard mammosphere medium contains 
phenol red-free DMEM/F12 (Gibco), B27 supplement (no vitamin A; Invitrogen) and 
recombinant epidermal growth factor (rEGF, 20 ng/ml; Sigma). Where indicated, cell were 
MATERIAL AND METHODS 
68 
 
plated in medium containing phenol red-free DMEM/F12, B27 supplement and 5% WF. In a 
subset of experiments, blocking antibody anti-IL6 (R&D Systems, 0.2µg/ml) or STAT3 
inhibitors (STAT3 inhibitor VI S3I-201 50µM for MDA-MB-231, 100µM for MDA-MB-468; 
STA-21 30µM for both the cell lines; STAT3 inhibitor V Stattic 10µM for both the cell lines 
and Galiellalactone 12µM for MDA-MB-231, 25µM for MDA-MB-468) were added at the 
medium. After ten days, primary mammospheres were counted using a 4X objective. To 
establish secondary mammospheres, primary mammospheres were collected, resuspended in  
0.5 % trypsin/0.2 % EDTA and disaggregate using 25-gauge needle fitted to a syringe. Cells 
were plated in the medium at the same seeding density that was used in the primary 
generation. Mammosphere forming efficiency (MFE%) was calculated as follows: number of 
mammospheres per well/number of cells seeded per well x 100. Mammosphere self-renewal 
was calculated as follows: total number of 2nd mammospheres formed/total number of 1st 
mammospheres formed. For more details see Ref 119. 
 
5.14. Immunoassay for the detection of phosphorylation of STAT proteins 
  The detection of the activation of STAT phospho-protein was performed using the Milliplex 
Map 5-Plex Human STAT Phosphoprotein Magnetic Bead Kit. MDA-MB-231 cells were 
starved and stimulated or not with WF 5% for 20 minutes and processed as indicated by the 
manufacturer’s instruction. 
 
5.15. In vivo experiments 
Primary tumors were established by injection of 2x106 MDA-MB-231 control or derived cell 
clones bilaterally in the fat pads of the thoracic mammary glands of female athymic nude 
mice (Harlan, 6-8 weeks old). As indicated, a subset of experiments was performed 
inoculating MDA-MB-231 control cell (2x106 or 1x106) in the left MFP and MDA-MB-231 
p70KR cells or MDA-MB-231 sh-STAT3 (2x106) in the controlateral one. Growth of primary 
tumors was monitored by measuring tumor length (L) and width (W), and calculating tumor 
volume based on the formula L x W2 / 2. For the evaluation of local relapse, pre-anesthetized 
mice underwent breast surgery to remove the primary tumors, when tumors reached a volume 
of 200-300 mm3. The appearance of locale recurrence was monitored by macroscopic 
examination of mice over a period of 8 weeks. Unless tumor burden was incompatible with 
the well-being of the animals, mice were sacrificed at the end of experiment. Recurrent 
disease or mammary glands, axillary/brachial lymph nodes and lungs were collected and 
stored together with the primary tumors for the subsequent analyses.  
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To evaluate the effect of PF-4708671 and Temsirolimus on the formation of recurrences, 
primary tumors were established by injection of 2x106 MDA-MB-231 control cells, as 
described above. The animals were randomly divided into groups according to experimental 
design (5 mice/control group, 5 mice/treatment/concentration). The administration of the 
drugs was performed following a “peri-operative schedule”.  Mice were intraperitoneally 
injected with PF-4708671 (600 µg per mouse, equivalent to 25 mg/kg, or 1200 µg per mouse, 
equivalent to 50 mg/kg, diluted in PBS) or Temsirolimus (300 µg per mouse, equivalent to 
12.5 mg/kg, or 600 µg per mouse,equivalent to 25 mg/kg, diluted in PBS) or vehicle (PBS) 
daily, for three days in succession. First treatment was on day -1, second on the day of surgery 
and third treatment on day +1. 
In the long-term treatment experiment, after the appearance of palpable primary tumors 
generated from MDA-MB-231 control cells, animals were intraperitoneally treated with PF-
4708671 (600 µg per mouse) or Temsirolimus (300 µg per mouse) twice a week, for three 
weeks. During treatment, growth of primary tumors was monitored and measured. Mice were 
sacrificed at the end point of the experiment. To evaluate the effect of the three-days schedule 
of treatment on tumor cells in vivo, primary tumors were established by injection of 2x106 
MDA-MB-231 control cells, bilaterally in thoracic MFP. When primary tumors reached a 
volume of 50-100 mm3, mice were intraperitoneally treated with PF-4708671 (3 mice/group, 
1200 µg/mouse) or with Temsirolimus (3 mice/group, 300 µg or 600 µg/mouse) or vehicle (3 
mice/group, PBS) daily, for three consecutive days. Mice were sacrificed one day after the 
last treatment. Tumors were collected and stored for subsequent analyses. To analyze the 
tumor take rate, mice were injected with 1x104  or 2x104 or 5x104 or 1x105 or 2x105 or 7.5x105 
or 2x106 MDA-MB-231 control or modified cells resuspended in 50 µl Matrigel/PBS (1:1). 
Growth of primary tumors was monitored up to 8 weeks. As an alternative approach, mice 
were injected with 1x105, 2x105 or 4x105 MDA-MB-231 control- or p70KR expressing-cells, 
without Matrigel, in 100µl of PBS. Growth of primary tumors was monitored up to 8 weeks. 
 
5.16. Statistical analyses 
Data were examined using the two-tailed Student t test or unpaired two-tailed Mann-Whitney 
U test. Differences were considered significant at p < 0.05. Significance in disease-free 
survival curve was calculated using Logrank test along with Hazard Ratio. The computer 
software PRISM (version 4, GraphPad, Inc.) was used to make graphs and all statistical 
analyses. 
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